

**CURRICULUM VITAE****NAME:** William Thomas Cefalu, M.D.**CURRENT POSITION:**

Chief Scientific, Medical & Mission Officer  
American Diabetes Association  
2451 Crystal Drive  
Arlington, VA 22202

**EDUCATION/TRAINING**

- 1983-1986 Fellowship in Endocrinology and Metabolism  
UCLA Center for Health Sciences  
Los Angeles, California
- 1982-1983 Chief Resident- Internal Medicine  
University of California - Irvine/Long Beach V.A. Medical Center  
Long Beach, California
- 1980-1982 Internal Medicine Residency  
University of California - Irvine/Long Beach V.A. Medical Center  
Long Beach, California
- 1979-1980 Internal Medicine Internship  
Louisiana State University School of Medicine  
Charity Hospital, New Orleans, Louisiana
- 1975-1979 Louisiana State University School of Medicine  
New Orleans, Louisiana  
M.D.
- 1972-1975 Southeastern Louisiana University  
Hammond, Louisiana  
B.S. (Biology)

**PROFESSIONAL LICENSURE:**

- 1979 State of Louisiana  
1980-86 State of California (Inactive)  
1988-98 State of North Carolina (Inactive)  
1998-2009 State of Vermont (Inactive)  
2003-Present State of Louisiana

**SPECIALTY CERTIFICATION:**

- 1986 American Board of Internal Medicine  
1989 ABIM - Subspecialty in Endocrinology and Metabolism  
1992-2002 ABIM - Subspecialty in Geriatrics/Gerontology

**PROFESSIONAL EXPERIENCE**

- 2017-present Chief Scientific, Medical & Mission Officer, American Diabetes Association, Arlington, Virginia
- 2017-present Professor Emeritus, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA
- 2015-2017 George A. Bray, Jr. Endowed Super Chair in Nutrition
- 2013-2017 Executive Director, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana
- 2012-2017 Director, NIH IDEA-CTR U54, Louisiana Clinical and Translational Science Center, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana
- 2013 Associate Executive Director of Scientific Affairs and Chief Scientific Officer, Pennington Biomedical Research Center, Baton Rouge, Louisiana
- 2012-2013 Associate Executive Director of Clinical Research, Pennington Biomedical Research Center, Baton Rouge, Louisiana
- 2011-2012 Assistant Executive Director of Clinical Research, Pennington Biomedical Research Center, Baton Rouge, Louisiana
- 2009-2012 Chief, Joint Program on Diabetes, Endocrinology, and Metabolism, LSUHSC School of Medicine & Pennington Biomedical Research Center, New Orleans & Baton Rouge, LA
- 2009-2013 Division Chief, Section on Endocrinology, Diabetes and Metabolism, Dep't of Medicine, Louisiana State University Health Science Center (LSUHSC) School of Medicine, New Orleans, La,
- 2009-2014 Director, Allen A. Copping In-Patient Research Unit, Pennington Biomedical Research Center, LSU System, Baton Rouge, Louisiana
- 2009-2012 Vice-Chair, Clinical Research, Department of Medicine, Louisiana State University Health Science Center School of Medicine, New Orleans, LA
- 2005-2017 Director, NIH Center for the Study of Botanicals and Metabolic Syndrome, Pennington Biomedical Research Center- Louisiana State University System and Rutgers University
- 2003-2015 Douglas L. Manship, Sr. Professor of Diabetes (Endowed) Pennington Biomedical Research Center, LSU System, Baton Rouge, LA

- 2003-2008 Chief, Division of Nutrition and Chronic Diseases  
Pennington Biomedical Research Center, Louisiana State University System,  
Baton Rouge, Louisiana
- 2003-2009 Adjunct Professor  
University of Vermont College of Medicine, Burlington, Vermont
- 2001-2003 Head, Clinical Trials Unit, Department of Medicine  
University of Vermont College of Medicine/Fletcher-Allen Health Care  
Burlington, Vermont
- 1998-2003 Associate Professor of Medicine  
University of Vermont College of Medicine, Burlington, Vermont
- 1994-1998 Associate Professor of Medicine  
Bowman Gray School of Medicine, Wake Forest University  
Winston-Salem, North Carolina
- 1989-1998 Director, Diabetes Comprehensive Care and Research Programs  
Bowman Gray School of Medicine, Wake Forest University  
Winston-Salem, North Carolina
- 1989-1998 Associate in Comparative Medicine  
Bowman Gray School of Medicine, Wake Forest University  
Winston-Salem, North Carolina
- 1988-1994 Assistant Professor of Medicine  
Section on Endocrinology, Department of Internal Medicine  
Bowman Gray School of Medicine, Wake Forest University  
Winston-Salem, North Carolina
- 1986-1988 Co-Medical Director  
Inpatient Unit, Tulane University School of Medicine Center for Diabetes  
New Orleans, Louisiana
- 1986-1988 Assistant Professor of Medicine  
Section on Endocrinology, Tulane School of Medicine  
New Orleans, Louisiana

## HONORS AND AWARDS

- 2018 Awarded the “Premio all Ricerca in Medicina” (Award for research in Medicine) on October 19, 2018 by the Schola Medica Salernitana (Medical School of Salerno, Italy).
- 2017 The Michael A. Kirschenbaum, M.D. Lecturer, University of California-Irvine
- 2017 Alumnus of the Year, Southeastern Louisiana University, Hammond, Louisiana

- 2013 The Josiah Brown Memorial Lecturer in Diabetes Research from the University of California, Los Angeles
- 1997 The Geron Corporation-Samuel Goldstein Distinguished Publication Award for the Best Paper Published in the Journal of Gerontology: Biological Sciences May 1996-March 1997. Manuscript entitled "A study of Caloric Restriction and Cardiovascular Aging in Cynomolgus Monkeys (*Macaca fascicularis*): A Potential Model for Aging Research"
- 1988-1989 Clinical Faculty Teaching Award  
Tulane University School of Medicine
- 1987-1988 C. Thorpe Ray Teaching Award for Excellence  
Tulane Medical School, Department of Medicine
- 1987-1988 Clinical Faculty Teaching Award  
Tulane University School of Medicine
- 1986-1987 Clinical Faculty Teaching Award  
Tulane University School of Medicine
- 1985 2nd Place, Fellows Research Competition  
Los Angeles Endocrine Club
- 1975 Outstanding Senior, Biological Sciences  
Southeastern Louisiana University

## PROFESSIONAL MEMBERSHIPS

The Endocrine Society

American Diabetes Association

North Carolina Affiliate Board of Directors (1992-1996)

President, North Carolina Affiliate, 1995-1996

Vice-President, North Carolina Affiliate, 1994-1995

Forsyth County Chapter Board of Directors (1989-1996)

President, Forsyth County Chapter (1991-1993)

State Board of Directors, Louisiana Affiliate, elected 1988, New Orleans Chapter

The Obesity Society

**SERVICE****Review/Editorial Boards:**

- Editor-In-Chief: Journal *Diabetes Care*, July 2011-March 2017
- Associate Editor: Journal *Diabetes*, July 2006 – June 2011
- Associate Editor: Journal *Diabetes Care*, 2004 – June 2006
- Editorial Board: Diabetes Research and Clinical Practice, 1993-2014.  
American Journal of Physiology: Endocrinology and Metabolism, 2000-2006  
Healthcare Journal of Baton Rouge, 2014-2016
- Reviewer: J Am Ger Soc, J Gerontology, Diabetes Care, Clinical Chemistry, Metabolism, Am J Phys, J Biol Chem, J Nutr, Diabetes, New England Journal of Medicine, J Clin Investigation, Am J Nutr, Lancet, Journal of Clinical Endocrinology and Metabolism

**Scientific Abstract Reviewer:****American Diabetes Association (ADA)**

- 2004 64<sup>th</sup> Annual Scientific Sessions, Orlando, Florida  
“Clinical Therapeutics, Pharmacologic Treatment of Diabetes or its Complications”
- 2005 65<sup>th</sup> Annual Scientific Sessions, San Diego, Ca  
“Clinical Therapeutics, Pharmacologic Treatment of Diabetes or its Complications”
- 2006 66<sup>th</sup> Annual Scientific Sessions, Washington, DC  
“Clinical Therapeutics/New Technology, Pharmacologic Treatment of Diabetes or its Complications”
- 2009 69<sup>th</sup> Annual Scientific Sessions, New Orleans, LA  
“Clinical Therapeutics/New Technology, Pharmacologic Treatment of Diabetes or its Complications”
- 2010 70<sup>th</sup> Annual Scientific Sessions, Orlando, Fla  
“Complications - Macrovascular - Atherosclerotic CVD and Human Diabetes”
- 2012 72<sup>nd</sup> Annual Scientific Sessions, Philadelphia, PA  
“Clinical Therapeutics/New Technology, Pharmacologic Treatment of Diabetes or its Complications”
- 2013 73<sup>rd</sup> Annual Scientific Sessions, Chicago, Ill  
“Clinical Therapeutics/New Technology – Insulin Delivery Systems”.

International Diabetes Foundation

2009 IDF, Montreal, Canada  
 “Therapies and Diabetes Clinical Management”

The Endocrine Society

2011 ENDO 2011: The 93rd Annual Meeting & Expo, Boston, MA  
 “Diabetes & Glucose Metabolism”

**Scientific Program Committees**

2014 50<sup>th</sup> Annual Meeting, European Association for the Study of Diabetes  
 Vienna, Austria

**Scientific Review Groups:**

1995-2002 National Scientific Advisory Council, American Federation for Aging Research

1995-1998 Scientific Review Committee - Juvenile Diabetes Foundation

2007-2008 Scientific Review Committee – American Diabetes Association

**NIH Study Sections:**

April 2001 NIA Special Emphasis Review Panel  
 RFA# AG-01-002 (Molecular and Neural Mechanisms Underlying the  
 Effects of Caloric Restriction on Health and Longevity)

June 2001 NIA Special Emphasis Panel Review Committee  
 RFA# AG-02-002 (Caloric Restriction and Aging in Non-Human  
 Primates)

March 2002 NIA Special Emphasis Panel Review Committee  
 RFA# ZAG1 ZIJ-5 M4 (Caloric Restriction)

August 2002 NIDDK Special Emphasis Panel Review Committee  
 RFA# DK-02-022 (Bench to Bedside Research on Type 1 Diabetes)

July 2004 NCCAM Special Emphasis Panel Review Committee (NCAAM SEP CP-  
 15) PAS 03-038 (Centers of Excellence for Research on  
 Complementary and Alternative Medicine (CERC))

October 2006- June 2009 Member, Clinical and Integrative Diabetes and Obesity (CIDO) Study  
 Section

June 2008	Chairman, NIH Special Emphasis Panel Review Committee, ZAT1 SM (11), Program Project Applications for PAR-06-047, Centers of Excellence for Research on Complementary and Alternative Medicine (CERC). June 25-27, 2009
March 2010	Chairman, NIH Special Emphasis Panel Review Committee, ZRG1 EMNR-K 90 S, Translational Diabetes and Obesity. March 16, 2010 - March 17, 2010
May 2010	Chairman, NIH Special Emphasis Panel/Scientific Review Group, ZRG1 EMNR-D (02), May 5, 2010 – May 6, 2010
March 2011	Chairman, NIH Center For Scientific Review Special Emphasis Panel ZRG1 EMNR-E 80 S, Diabetes, Obesity and Endocrine Disorders March 23, 2011-March 24, 2011
March 2011	Stage 1 Reviewer, NIH Director's Early Independence Award Application Review ZRG1 BBBP-E (53)R. Meeting Dates: 06/13/2011-06/14/2011
February 2012	Kidney, Nutrition, Obesity and Diabetes (KNOD) Study Section; Ad hoc Reviewer, NIH Center For Scientific Review, Bethesda, MD, February 2012
May 2012	Chairman, NIH Center For Scientific Review, ZRG1 EMNR-K (80) S Translational Research in Diabetes, Obesity and Endocrine Disorders June 27-28, 2012
2012-2016	Member, Kidney, Nutrition, Obesity and Diabetes (KNOD) Study Section, NIH Center for Scientific Review, Bethesda, MD

### **National Committees**

2014-2016	American College of Cardiology Publications and Editorial Coordination Committee
2008-2011	Professional Development Committee, The Endocrine Society
2008-2011	National Research Policy Committee, American Diabetes Association
2006	Disaster Response Task Force, American Diabetes Association
2001-2012	Council for the Advancement of Diabetes Research and Education (CADRE) Co-Chair, 2001-2012; President, Board of Directors, 2002-2012

**OTHER PROFESSIONAL APPOINTMENTS AND ACTIVITIES:**

- 2006-2008 Chairman, Medical Advisory Board for Human Inhaled Insulin Program, Eli Lilly, Inc.
- 2006-2008 Chairman, Medical Advisory Board for Incretin Hormones Amylin Pharmaceuticals, Inc.
- 1987-1988 American Diabetes Association Diabetic Camp, Independence, LA  
Associate Director/Academic Director, Medical Student Research Program

**GRANT SUPPORT (History of Funding: All active wards were transferred to other principal investigators at the institution when I left Pennington Biomedical to take a position at the American Diabetes Association in February 2017)**

**I. National Institutes of Health****Title: Louisiana Clinical and Translational Science Center (LA CaTS)**

Role: Principal Investigator Duration: 08/15/2012 - 06/30/2022\*  
Effort: 40% Grant Number: NIH 1U54GM10494-01  
Total Funding for years 2012-2022: \$39,800,000  
\* Successfully renewed the center for a 2<sup>nd</sup> 5 year cycle through 2022

The Louisiana Clinical and Translational Science (LA CaTS) Center, with Pennington Biomedical Research Center in Baton Rouge, Louisiana, as the lead institution, has as its mission to “*encourage, support, and expand clinical and translational research through partnerships both among researchers and with the people we serve*”. As a primary objective, the LA CaTS Center builds upon the structure of the COBREs and INBREs of the state. The primary collaborating institutions are LSU Health Sciences Center in New Orleans, Tulane University Health Sciences Center and LSU Health Care Services Division (hospitals and clinics). The Specific Aims are: 1) Create a collaborative infrastructure for clinical and translational research both within and across participating institutions; 2) Increase the critical mass of investigators performing clinical and translational research; and 3) Improve and sustain bi-directional relationships with our communities.

**Title: Botanical Research Center: Botanicals and Metabolic Syndrome**

Role: Principal Investigator/Center Director; Project 1 Leader  
% Effort: 25% Duration: 09/01/15- 8/20/20\*  
Total Funding for years 2010-2015: \$9,200,000 Grant Number: NIH 3P50AT002776  
\*Successfully renewed the center for a 3<sup>rd</sup> 5 year cycle

**Center Summary:** The Botanical Research Center is one of 3 NIH funded Centers of Excellence in botanical research and the one center primarily focusing on obesity and pre-diabetes. Our Center is a collaborative effort between the Pennington Biomedical Research Center of the Louisiana State University (LSU) System and the Center of Agriculture and the Environment of Rutgers University. The theme of our Center is “Botanicals and Metabolic Resiliency”.



**Title:     *Training in Botanical Approaches to Combat Metabolic Syndrome***

Role:        Co-Program Director                    Duration:        05/01/2009–04/30/2014  
 PI: Brantely    Grant Number: NIH 1T32 AT004094  
 Total Funding: \$1,811, 266

The specific aims of the T32 proposal are to provide training opportunities for post-doctoral training in pre-clinical aspects evaluating botanicals and metabolic syndrome. The mentors for the grant are part of the NIH funded Botanical Research Center for which Dr. Cefalu serves as Center Director. Currently there are 5 PhD/MD positions for the first year, and 7 positions thereafter. The goal is to expand the critical mass of investigators in obesity/metabolic research and evaluation of botanical therapeutics.

**Title:     *Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness (GRADE) Study***

Role: PI (Pennington Study Site)    12/01/2012 - 11/31/2020  
 George Washington University   \$204,627 (Year 1)

The major specific aims include to compare the relative attributes of five commonly used anti diabetic medications on efficacy and complications. Pennington serves as a clinical study site

**Title:     *Nutritional Programming: Environmental and Molecular Interactions***

Role:        Core Leader, Human Phenotyping Core    Duration: 09/01/2010–08/31/2015  
 % Effort: 15%   Grant Number: NIH P30-DK074276  
 PI: Ravussin  
 Total Funding: \$3,750,000

The Pennington Biomedical Research Center Nutrition Obesity Research Center will continue to facilitate and promote collaborative and multi-disciplinary interactions that will foster new research ideas and enhance the translation of basic nutritional research findings into the clinical arena and ultimately into practical application.

**Title:     *Botanicals and Metabolic Syndrome (Administrative Supplement 1)***

3 P50 AT002776 Role: PI (Cefalu)    07/01/2011 - 06/30/2012  
 NIH   \$128,570

Overall, the goals are: 1) To utilize the Botanical Core of the PBRC/RU Center to further characterize *Sutherlandia* extracts, since insulin action is a major focus of PBRC/RU and *Sutherlandia* has clinical effects on carbohydrate metabolism similar to those botanicals studied by the PBRC/RU Center; 2) To specifically investigate the cellular effects of *Sutherlandia*, with a focus on the signaling components that have been identified for *Artemisia* species with similar biological effects; 3) To utilize CORE D of UM (Mega sequencing, Proteomics, Informatics and Nitrosylation) to evaluate microRNAs from in vitro and in vivo experiments so as to further investigate the cellular effects by which botanicals



**Title: *Combinatorial Library Screening with Human ADAS Cells***

Role: Co-Investigator                      Duration: 06/01/2008 – 5/31/2009  
% Effort: 5%                                      Grant Number: NIH 1R41 AR052542  
PI: Gimble, J

This project's overall objective was to develop high throughput screening assays using adult derived stromal stem cells to evaluate promising candidate agents that may have an effect on adipogenesis.

**Title: *Chromium, Cellular Energy Status and Whole Body Energy Balance***

Role: Principal Investigator                  Duration: 07/01/05-6/30/08  
% Effort: 20%                                      Grant Number: NIH 1R21AT002995-01

Total Funding: \$588,000

This project's overall objective was to perform exploratory studies on the effect of chromium on whole body energy balance, lipid metabolism, and cellular energy status in subjects with Type 2 diabetes. We hypothesized that, in subjects with type 2 diabetes, Cr will enhance cellular AMP kinase activation resulting in an increase in skeletal muscle lipid metabolism and adipose tissue function. These findings will be associated with an improved whole body energy balance.

**Title: *Caloric Restriction and Cardiovascular Aging***

SERCA (Special Emphasis Research Career Development Award)

Role: Principal Investigator                  Duration: 09/92 - 08/97  
% Effort: 75%                                      Grant Number: NIH K01AG000578

The proposed research evaluated a well characterized non -human primate model for human atherosclerosis and studied dietary intervention in the form of caloric restriction compared to unrestricted diet with equivalent cholesterol content. We evaluated for changes secondary to the dietary restriction on insulin resistance, arterial collagen glycation/advanced glycation, and adipose distribution, all of which have been strongly implicated in contributing to cardiovascular disease.

**Title: *Caloric Restriction, Aging and Cardiovascular Disease***

FIRST Award (First Independent Research Transition Award)

Role: Principal Investigator                  Duration: 06/93 - 08/98  
% Effort: 25    Grant Number: NIH R29 AG010816

The proposed research provided the financial support and supplies in support of the SERCA Award (AG000578). The study evaluated a well characterized non -human primate model for human atherosclerosis and studied dietary intervention in the form of caloric restriction compared to unrestricted diet with equivalent cholesterol content. We evaluated for changes secondary to the dietary restriction on insulin resistance, arterial collagen glycation/advanced glycation, and adipose distribution, all of which have been strongly implicated in contributing

to cardiovascular disease.

**Title:     *Caloric Restriction, Aging and Insulin Action***

Role:       Principal Investigator                   Duration:       04/99 - 03/03  
% Effort:   25   Grant Number:  NIH R01 AG15823

This study evaluated the mechanism by which caloric restriction enhances insulin action. Tissues from a 5-year nonhuman primate trial evaluating the effect of caloric restriction on atherosclerosis extent were used as the tissue source. Specific measures of intra-cellular signaling were assessed to determine the cellular mechanism by which caloric restriction enhances insulin sensitivity.

**Title:     *Bypass Angioplasty Revascularization Investigation II - Diabetes (BARI 2D)***

Role:       Diabetology PI (09/00-08/03)           Duration:       09/29/00-09/28/07  
% Effort:   5%   Grant Number:  NIH HL61744

This study is a multi-center, randomized trial to determine, in patients with type 2 diabetes and documented stable coronary artery disease: 1) the efficacy of initial elective coronary revascularization combined with aggressive medical therapy, compared to aggressive medical therapy alone; and 2) the efficacy of providing more insulin (endogenous or exogenous) versus increasing sensitivity to insulin (reducing insulin resistance) in the management of hyperglycemia.

**Title:     *Chromium and Insulin Action***

Role:       Principal Investigator                   Duration:       09/01/01-08/30/02  
% Effort:   15%   Grant Number:  NIH R55 DK060126

This study evaluated the cellular mechanism by which chromium picolinate may improve insulin action in skeletal muscle in patients with type 2 diabetes.

**II.   Foundations (Past Funding)**

**A.   United States HBBC (USDA Oversight)**

**Title:     **The Effect of Anthocyanin Enriched Extracts on Cardiovascular Disease Risk Factors in Human Subjects with Metabolic Syndrome****

Role:       Principal Investigator                   Duration:       05/01/10 – 4/30/13  
% Effort:   AR  
Total Funding: \$247,000

This project's overall objective is to perform human studies in subjects with metabolic syndrome and evaluating the effect of dietary supplementation with an anthocyanin rich extract on specific cardiovascular risk factors.

**B.   Coypu Foundation**

**Title:     *Establishment of the John L. McIlhenny Laboratory***

Role:       Principal Investigator                   Duration:       12/05 – 12/10  
 % Effort:   AR    Total Funding: \$350,000

Funding from the Coypu foundation was used to establish the *John L. McIlhenny Laboratory*. This goal of this laboratory is to develop a high throughput testing system for promising compounds and bioactives proposed to have effects to improve insulin action. Specifically, we have developed a pre-clinical testing paradigm to assess the effect of botanicals, and their bioactive components, on selected cellular pathways proposed to modulate development of insulin resistance in vivo. Employing relevant cell culture systems, bioactive compounds are assessed for their ability to affect 1) glycogen synthesis; 2) fatty acid oxidation, 3) mitochondrial biogenesis; 4) adipogenesis; 5) adiponectin secretion; and 6) selected gene promoter activity (TNF $\alpha$ , NF- $\kappa$ B, PPAR- $\gamma$ , adiponectin).

**C. United States HBBC (USDA Oversight)****Title:     **The Effect of Anthocyanin Preparations from Blueberries on Insulin Sensitivity in Human Subjects****

Role:       Principal Investigator                   Duration:       02/01/08 – 7/01/09  
 % Effort:   AR%  
 Total Funding: \$161,500

This project's overall objective is to perform pilot human studies evaluating the effect of anthocyanins (from Blueberry extract) on carbohydrate metabolism in humans. Specifically, insulin resistant, obese subjects will consume, on a daily basis, a determined quantity of blueberry powder incorporated as part of a eucaloric diet and the effect on insulin sensitivity (Hyperinsulinemic Euglycemic Clamps) will be obtained prior to randomization and after 6 weeks of dietary consumption

**III. American Diabetes Association (Past Funding)****Title:     ***Chromium and Insulin Action*****

Role:       Principal Investigator                   Duration:       01/01/01-12/30/03  
 % Effort:   15%

This study evaluated the role of a nutrient, chromium picolinate, to improve insulin resistance in patients with type 2 diabetes, and will explore the cellular mechanism by which insulin action may be enhanced.

**GRANT SUPPORT:** **Industry** (*I have served as the PI for over 50 industry-sponsored studies including sponsors such as Sanofi, Novo-Nordisk, Merck, Pfizer, Novartis, Lilly, Amylin, GlaxoSmithKline, Astra-Zeneca, Bristol-Myers Squib, Johnson and Johnson.*)

**BIBLIOGRAPHY:**BOOKS: AUTHORED

**Cefalu WT**, Stop Diabetes Now. Penguin Publishing, NY, NY, 2008

**Cefalu, WT**: Practical Guide to Diabetes Management, 2<sup>nd</sup> ed. CMD Publishing, NY, NY, 2001.

**Cefalu, WT**: Practical Guide to Diabetes Management. CMD Publishing, NY, NY, 1998.

BOOKS: EDITED

Insulin Therapy and Practice (Leahy J and **Cefalu WT**, eds.). Endocrinol Metab Clin North Am. 2012

Atlas of Cardiometabolic Risk (**Cefalu WT** and Cannon CP, eds). Informa Healthcare USA, Inc. New York, NY 2007

CADRE's Handbook of Diabetes Management (**Cefalu WT**, Leroith D, Gerich J, eds). CMD Publishing NY, NY 2004

Insulin Therapy (Leahy J and **Cefalu WT**, eds.). New York: Marcel Dekker, Inc. 2002

The Medical Management of Diabetes Mellitus (Leahy J, Clark N, and **Cefalu WT**, eds.). New York: Marcel Dekker, Inc., 2000

CHAPTERS IN BOOKS

Champagne CM, Greenway FL, **Cefalu WT**. Obesity and type 2 diabetes. In Therapy for Diabetes Mellitus and Related Disorders. 6th ed. Umpierrez GE, Ed. Alexandria, VA, American Diabetes Association, 2014, p. 239-262.

Stull A, Champagne C, **Cefalu WT**. Lifestyle Approaches to the Metabolic Syndrome (Chapter 36), In Lifestyle Medicine, Second Edition, Rippe J, Editor, Taylor and Francis, 2013

**Cefalu WT**, Stephens JM, Ribnicky DM. Diabetes and Herbal (Botanical) Medicine. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press; 2011. Chapter 19.

Elks CM, Francis J, Stull AJ, **Cefalu WT**, Shukitt-Hale B, Ingram D. Overview of the Health Properties of Blueberries. Editors: Margot Skinner PhD and Denise Hunter PhD. Publisher: Wiley-Blackwell (2012)

Richards RJ, Melendez-Ramirez, LY, **Cefalu WT**. Insulin Sensitizers vs. Secretagogues as First Line Therapy for Diabetes: Rationale for Clinical Choice. In. Clinical Dilemmas in Diabetes Editors Vella A and Rizza RA, Wiley-Blackwell Publishers, Oxford UK (2010)

**Cefalu WT**, Champagne C, Greenway F. Weight Loss Agents and Metabolic Syndrome. In Therapeutic Strategies for Metabolic Syndrome (Fonseca V, ed), Clinical Publishing, Oxford, United Kingdom 2008

**Cefalu WT**. Physiologic Systems Regulating Energy Balance, including the EC system. Chapter 4, pp 55-68, in Atlas of Cardiometabolic Risk (Cefalu WT and Cannon CP, eds), Informa Healthcare USA, Inc, New York, NY 2007

**Cefalu WT**. Role of obesity and body fat distribution in cardiometabolic risk. Chapter 3, pp 39- 54, in Atlas of Cardiometabolic Risk (Cefalu WT and Cannon CP, eds), Informa Healthcare USA, Inc, New York, NY 2007

**Cefalu WT**. Insulin Resistance and Cardiometabolic Risk. Chapter 2, pp 27-38, in Atlas of Cardiometabolic Risk (Cefalu WT and Cannon CP, eds), Informa Healthcare USA, Inc, New York, NY 2007

**Cefalu WT**. Classification and evolution of increased cardiometabolic risk states. Chapter 1, pp 13-16, in Atlas of Cardiometabolic Risk (Cefalu WT and Cannon CP, eds), Informa Healthcare USA, Inc, New York, NY 2007

**Cefalu WT**, Greenway F: Obesity and its treatment in Type 2 diabetes. In Type 2 Diabetes Mellitus: An Evidence Based Approach to Practical Management (Feinglos M, Ed), Humana Press, 2007

**Cefalu WT**: Clinical Effects of Chromium Supplements on Human Health, Chapter 8, pp. 163 – 181. In: The Nutritional Biochemistry of Chromium (III) (Vincent JB, Ed), Elsevier Press, 2007.

**Cefalu WT**, Greenway F: Pharmacologic Agents and Nutritional Supplements in the Treatment of Obesity, Chapter 3, pp. 417 – 428.. In Diabetes Mellitus: Translating Research to Clinical Practice (Fonseca V, Eds), Elsevier Press, 2006.

Anderson, Richard; **Cefalu, William**. Chromium. In Encyclopedia of Dietary Supplements, 1st Ed., Online Updates; Coates, P., Blackman, M., Cragg, G., Levine, M., Moss, J., White, J., Eds.; Marcel Dekker, Inc.: New York, 2005.

**Cefalu WT**. Rationale for and Strategies to Achieve Glycemic Control. In: Insulin Therapy (Leahy J and Cefalu WT, eds.). New York: Marcel Dekker, Inc. 2002.

**Cefalu WT**. Non-invasive Insulin Delivery Systems: Options and Progress to Date. In: Insulin Therapy (Leahy J and Cefalu WT, eds.). New York: Marcel Dekker, Inc. 2002.

**Cefalu, WT**. Recognition and Assessment of Insulin Resistance. In: Diabetes, The Heart, and Cardiovascular Disease (Sobel BE and Schneider DJ, eds.). New York: Marcel Dekker, Inc. 2002.

Wagner JD, Williams JK, Adams MR, Anthony MS, **Cefalu WT**, Clarkson TB. Effects of mammalian estrogens and phytoestrogens on the vascular system. In: Lippert TH, Mueck AO, Ginsburg J, eds. Sex Steroids and the Cardiovascular System: The Proceedings of the

1st Interdisciplinary Workshop Tuebingen, Germany, October 1996. Carnforth, U.K.: Parthenon Publishing, 1998:21-33.

Anderson RA, **Cefalu WT**, Jeejeebhoy KN, Kaats, GR. Role of Chromium in Glucose Intolerance, Diabetes, Total Parenteral Nutrition, and Body Composition. In: Trace Elements in Man and Animals 10 (Roussel AM, Anderson RA, and Favier AE, eds.). Kluwer Academic/Plenum Publishers, New York, 2000; 503-509.

**Cefalu WT**. Insulin Resistance/Syndrome X. In: The Medical Management of Diabetes Mellitus (Leahy J, Clark N, Cefalu WT, eds.). New York: Marcel Dekker, Inc., 2000; 57-75.

Bloomfield R, Buckalew V, ed. Systemic Hypertension: A Multi-disciplinary Approach. Chap 6 - An Endocrinologist's Viewpoint. Carolina Academic Press, Durham, NC, 1994.

**Cefalu WT**. Diabetic ketoacidosis. In: Conn's Current Therapy (Raskel RE, ed.). W.B. Saunders, Inc.; 1994; 499.

Zaloga G, Ober P, **Cefalu WT**. Endocrine consultation. In: Manual of Clinical Anesthesia (Kirby RR, Gravenstein, eds.). W.B. Saunders; 1994; 185.

**Cefalu W**. Diabetic ketoacidosis. In: Critical Care Clinics (Zaloga G, ed.). W.B. Saunders, Inc.; 1991; 89-108.

**Cefalu W**, Clements R. Diabetic neuropathy. In: Diabetes and vascular disease (Kerstein M, ed.). J.D. Lippincott, Philadelphia, 1990; 163-180.

JOURNAL ARTICLES FOR SPECIAL SUPPLEMENT OF **NUTRITION** (SERVED AS GUEST EDITOR)

**Cefalu WT**, Floyd ZE, Ribnicky DM, Stephens JM. Botanicals and translational medicine: A paradigm shift in research approach. *Nutrition* 2014;30(7-8): S1-3.

Rood JC, Schwarz J-M, Gettys TW, Mynatt RL, Mendoza T, Johnson WD, **Cefalu WT**. The effects of *Artemisia sp.* on de novo lipogenesis *in vivo*. *Nutrition* 2014;30(7-8), S17-20.

Obanda DN, Ribnicky DM, Raskin I, **Cefalu WT**. Bioactives of *Artemisia dracunculus* L. enhance insulin sensitivity by modulation of ceramide metabolism in rat skeletal muscle cells. *Nutrition* 2014;30(7-8), Suppl, S59-66.

Ribnicky DM, Roopchand DE, Poulev A, Kuhn P, **Cefalu WT**, Raskin I. *Artemisia dracunculus* L. polyphenols complexed to soy protein show enhanced bioavailability and hypoglycemic activity in C57BL/6 mice. *Nutrition* 2014;30(7-8), S4-10.

Kirk-Ballard H, Kilroy G, Day BC, Wang ZQ, Ribnicky DM, **Cefalu WT**, Floyd ZE. An ethanolic extract of *Artemisia dracunculus* L. regulates gene expression of ubiquitin-proteasome system enzymes in skeletal muscle: Potential role in the treatment of sarcopenic obesity. *Nutrition* 2014;30(7-8), S21-5.



Kheterpal I, Scherp P, Kelley L, Wang Z, Johnson WD, Ribnicky DM, **Cefalu WT**. Bioactives from *Artemisia dracuncululus* L. Enhance Insulin Sensitivity via Modulation of Skeletal Muscle Protein Phosphorylation. *Nutrition* 2014; 30(7-8), S43-51.

Wicks SE, Taylor CM, Luo M, Blanchard IV E, Ribnicky DM, **Cefalu WT**, Mynatt RL, Welso DA. *Artemisia* supplementation differentially affects the mucosal and luminal ileal microbiota of diet-induced obese mice. *Nutrition* 2014; 30 (7-8), S26-30.

Boudreau A, Cheng DM, Ruiz C, Ribnicky D, Allain L, Brassieur CR, Turnipseed DP, **Cefalu WT**, Floyd ZE. Screening native botanicals for bioactivity: an interdisciplinary approach. *Nutrition*. 2014 Jul-Aug; 30 (7-8 Suppl):S11-6.

#### JOURNAL ARTICLES

Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, Brown AS, Heinemann L, Aleppo G, Ryan DB, Riddlesworth TD, **Cefalu WT**. Response to Comment on Bergenstal et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. *Diabetes Care* 2018;41:2275-2280.

Draznin, B, Nathan DM, Korytkowski MT, McDonnell ME, Golden SH, Schutta MH, **Cefalu WT**. Guidelines Versus Guidelines. *Ann Intern Med*. 2018 Dec 18; 169(12):896-897.

Writing Committee, Das SR, Everett BM, Birtcher KK, Brown JM, **Cefalu WT**, Januzzi JL Jr, Rastogi Kalyani R, Kosiborod M, Magwire ML, Morris PB, Sperling LS. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol*. 2018 Nov 24. pii: S0735-1097(18)38498-5. doi: 10.1016/j.jacc.2018.09.020.

Riddle MC, **Cefalu WT**. SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True? *Diabetes Care*. 2018 Dec;41(12):2444-2447.

Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, Brown AS, Heinemann L, Aleppo G, Ryan DB, Riddlesworth TD, **Cefalu WT**. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. *Diabetes Care*. 2018 Nov;41(11):2275-2280.

Fuller S, Yu Y, Mendoza T, Ribnicky DM, **Cefalu WT**, Floyd ZE. Potential adverse effects of botanical supplementation in high-fat-fed female mice. *Biol Sex Differ*. 2018 Sep 12;9(1):41.

Petersen MP, **Cefalu WT**. Identifying Trends in Undiagnosed Diabetes in U.S. Adults. *Ann Intern Med*. 2018 Jun 19;168(12):900.

Draznin B, Nathan DM, Korytkowski MT, McDonnell ME, Golden SH, Schutta MH, **Cefalu WT**. Guidelines versus Guidelines: What's Best for the Patient. *Ann Intern Med*. 2018 May 22. doi: 10.7326/M18-0939.

Riddle MC, Gerstein HC, Holman RR, Inzucchi SE, Zinman B, Zoungas S, **Cefalu WT**. A1C Targets Should be Personalized to Maximize Benefits While Limiting Risks. *Diabetes Care*. 2018 Jun;41(6):1121-1124. doi: 10.2337/dci18-0018.

Sutton EF, Beyl R, Early KS, **Cefalu WT**, Ravussin E, Peterson CM. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. *Cell Metab*. 2018 Jun 5;27(6):1212-1221

**Cefalu WT**, Dawes DE, Gavlak G, Goldman D, Herman WH, Van Nuys K, Powers AC, Taylor SI, Yatvin AL; Insulin Access; Affordability Working Group. Insulin Access and Affordability Working Group: Conclusions and Recommendations. *Diabetes Care*. 2018 41(6):1299-1311

Broskey NT, Obanda DN, Burton JH, **Cefalu WT**, Ravussin E. Skeletal muscle ceramides and daily fat oxidation in obesity and diabetes. *Metabolism*. 2018 May;82:118-123.

Yu Y, Mendoza TM, Ribnicky DM, Poulev A, Noland RC, Mynatt RL, Raskin I, **Cefalu WT**, Floyd ZE. An Extract of Russian Tarragon Prevents Obesity-Related Ectopic Lipid Accumulation. *Mol Nutr Food Res*. 2018 Apr;62(8)

Petersen MP, Hirsch IB, Skyler JS, Ostlund RE, **Cefalu WT**. In Response to Carter and Heinemann: Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply Chain. *J Diabetes Sci Technol*. 2018 Jul;12(4):890-891.

**Cefalu WT**, Berg EG, Petersen MP, Darsow T. American Diabetes Association's Standards of Care: A Paradigm Shift in the Dissemination of Information. *Diabetes Care*. 2018 Mar;41(3):387-388.

Clark RV, Walker AC, Miller RR, O'Connor Semmes RL, Ravussin E, **Cefalu WT**. Creatine (methyl-d<sub>3</sub>) dilution in urine for estimation of total body skeletal muscle mass-accuracy and variability vs. MRI and DXA. *J Appl Physiol (1985)*. 2017 Aug 31:jap.00455.2016.

**Cefalu WT**, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a **Diabetes Care** Editors' Expert Forum. *Diabetes Care* 2018 Jan; 41 (1) 14-31.

Riddle MC, Gerstein HC, **Cefalu WT**. Maturation of CGM and Glycemic Measurements Beyond HbA<sub>1c</sub>-A Turning Point in Research and Clinical Decisions. *Diabetes Care*. 2017 Dec; 40 (12) 1611-1613.

**Cefalu WT**. *Diabetes Care: Change Is Constant, Part 2*. *Diabetes Care*. 2017 Aug;40(8):991-993.

Kalyani RR, Golden SH, **Cefalu WT**. Diabetes and Aging: Unique Considerations and Goals of Care. *Diabetes Care*. 2017 Apr;40 (4):440-443.

**Cefalu WT**, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE. Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. *Diabetes Care* 2016; 39:1186-1201. *Diabetes Care* 2017 Feb; 40 (2):e23-e24.

Hsia DS, Grove O, **Cefalu WT**. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. *Curr Opin Endocrinol Diabetes Obes*. 2017 Feb;24(1):73-79

**Cefalu WT**, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Kahn SE, Weinger K, Blonde L, de Groot M, Rich S, D'Alessio D, Reynolds L, Riddle MC. Diabetes Care: "Taking It to the Limit One More Time". *Diabetes Care*. 2017 Jan;40(1):3-6.

Weinger K, de Groot M, **Cefalu WT**. Psychosocial Research and Care in Diabetes: Altering Lives by Understanding Attitudes. *Diabetes Care*. 2016 Dec;39(12):2122-2125

Ryan DH, Hansen BC, **Cefalu WT**. George A. Bray, MD: Progress in Obesity-Multidisciplinary Research, Multidimensional Man. *Diabetes Care*. 2016 Sep;39(9):1481-5. Erratum in: *Diabetes Care*. 2016 Dec 27.

Rich SS, **Cefalu WT**. The Impact of Precision Medicine in Diabetes: A Multidimensional Perspective. *Diabetes Care*. 2016 Nov;39(11):1854-1857

**Cefalu WT**. "Prediabetes": Are There Problems With This Label? No, We Need Heightened Awareness of This Condition! *Diabetes Care*. 2016 Aug;39(8):1472-7.

Cahn A, **Cefalu WT**. Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes. *Diabetes Care*. 2016 Aug;39 Suppl 2:S137-45.

Raz I, **Cefalu WT**, Ilkova H, Del Prato S. Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). *Diabetes Care*. 2016 Aug;39 Suppl 2:S113-4.

Leiter LA, **Cefalu WT**, de Bruin TW, Xu J, Parikh S, Johnsson E, Gause-Nilsson I. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. *Diabetes Obes Metab*. 2016 Aug;18(8):766-74.

**Cefalu WT**, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Rich SS, D'Alessio D, Riddle MC, Reynolds L. Diabetes Care: "Lagniappe" and "Seeing Is Believing"! *Diabetes Care*. 2016 Jul;39(7):1069-71.

**Cefalu WT**, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. *Diabetes Care*. 2016 Jul;39(7):1186-201

Kovatchev B, Tamborlane WV, **Cefalu WT**, Cobelli C. The Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes. *Diabetes Care*. 2016 Jul;39(7):1123-6

Schatz D, **Cefalu WT**. Reevaluation of CMS' Competitive Bidding Program. *Diabetes Care*. 2016 Jul;39(7):1078-9.

**Cefalu WT**, Rubino F, Cummings DE. Metabolic Surgery for Type 2 Diabetes: Changing the Landscape of Diabetes Care. *Diabetes Care*. 2016 Jun;39(6):857-60.

**Cefalu WT**, Rosenstock J, LeRoith D, Blonde L, Riddle MC. Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory". *Diabetes Care*. 2016 May;39(5):664-7.

Obanda DN, Zhao P, Richard AJ, Ribnicky D, **Cefalu WT**, Stephens JM. Stinging Nettle (*Urtica dioica* L.) Attenuates FFA Induced Ceramide Accumulation in 3T3-L1 Adipocytes in an Adiponectin Dependent Manner. *PLoS One*. 2016 Mar 3;11(3):e0150252.

Obanda DN, Ribnicky D, Yu Y, Stephens J, **Cefalu WT**. An extract of *Urtica dioica* L. mitigates obesity induced insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A). *Sci Rep*. 2016 Feb 26;6:22222.

**Cefalu WT**, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Hill Golden S, Rich SS, D'Alessio D, Reynolds L. Building Momentum: Taking on the Real "Issues" of Diabetes Care! *Diabetes Care*. 2016 Jan;39(1):10-12

Moses RG, **Cefalu WT**. Considerations in the Management of Gestational Diabetes Mellitus: "You Are What Your Mother Ate!." *Diabetes Care*. 2016 Jan;39(1):13-5

**Cefalu WT**, Rosenstock J, LeRoith D, Riddle MC. Insulin's Role in Diabetes Management: After 90 Years, Still Considered the Essential "Black Dress". *Diabetes Care*. 2015 Dec;38(12):2200-3.

Cahn A, Raz I, Kleinman Y, Balicer R, Hoshen M, Lieberman N, Brenig N, Del Prato S, **Cefalu WT**. Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. *Diabetes Care*. 2015 Dec;38(12):2293-300.

**Cefalu WT**, Bray GA, Home PD, Garvey WT, Klein S, Pi-Sunyer FX, Hu FB, Raz I, Van Gaal L, Wolfe BM, Ryan DH. Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. *Diabetes Care*. 2015 Aug; 38(8):1567-82.

**Cefalu WT**, Chiang JL. Guiding Principles for Diabetes Care. *Diabetes Care*. 2015 Oct; 38(10):1955-7.

Gao Y, Li Z, Gabrielsen JS, Simcox JA, Lee SH, Jones D, Cooksey B, Stoddard G, **Cefalu WT**, McClain DA. Adipocyte iron regulates leptin and food intake. *J Clin Invest*. 2015 Sep 1;125(9):3681-91.

Waterman C, Rojas-Silva P, Tumer TB, Kuhn P, Richard AJ, Wicks S, Stephens JM, Wang Z, Mynatt R, **Cefalu WT**, Raskin I. Isothiocyanate-rich *Moringa oleifera* extract reduces weight gain, insulin resistance, and hepatic gluconeogenesis in mice. *Mol Nutr Food Res*. 2015 Jun;59(6):1013-24.

Hsia DS, Larrivee S, **Cefalu WT**, Johnson WD. Impact of Lowering BMI Cut Points as Recommended in the Revised American Diabetes Association's Standards of Medical Care in Diabetes-2015 on Diabetes Screening in Asian Americans. *Diabetes Care*. 2015 Nov; 38(11):2166-8.

**Cefalu WT**, Boulton AJ, Boulton AJ, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry R, Golden SH, Rich S, Reynolds L. Status of Diabetes Care: New Challenges, New Concepts, New Measures—Focusing on the Future. *Diabetes Care* 2015; Jul; 38(7); 1177-80

Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, **Cefalu WT**, Strumph P. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. *Diabetes Care*. 2015 Jul; 38(7):1181-8.

**Cefalu WT**, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. *Diabetes Care*. 2015 Jul;38(7):1218-27.

Brownley KA, Boettiger CA, Young L, **Cefalu WT**. Dietary chromium supplementation for targeted treatment of diabetes patients with comorbid depression and binge eating. *Med Hypotheses*. 2015 Jul;85(1):45-8.

Obanda DN, Yu Y, Wang ZQ, **Cefalu WT**. Modulation of sphingolipid metabolism with calorie restriction enhances insulin action in skeletal muscle. *J Nutr Biochem*. 2015 Jul;26(7):687-95.

**Cefalu WT**, Stenlöf K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. *Diabetologia*. 2015 Jun;58(6):1183-7.

**Cefalu WT**, Tamborlane WV, Skyler JS. Type 1 diabetes at a crossroads! *Diabetes Care*. 2015 Jun;38(6):968-70.

Stull AJ, Cash KC, Champagne CM, Gupta AK, Boston R, Beyl RA, Johnson WD, **Cefalu WT**. Blueberries improve endothelial function, but not blood pressure, in adults with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial. *Nutrients*. 2015 May 27;7(6):4107-23.

**Cefalu WT**, Petersen MP, Ratner RE. Response to comment on Cefalu et Al. The alarming and rising costs of diabetes and prediabetes: a call for action! *Diabetes care* 2014;37:3137-3138. *Diabetes Care*. 2015 May;38(5):e82-3.

Herman WH, **Cefalu WT**. Health policy and diabetes care: is it time to put politics aside? *Diabetes Care*. 2015 May;38(5):743-5.

**Cefalu WT**, Riddle MC. SGLT2 inhibitors: the latest "new kids on the block"! *Diabetes Care*. 2015 Mar;38(3):352-4.

Rosenstock J, **Cefalu WT**, Lapuerta P, Zambrowicz B, Ogbaa I, Banks P, Sands A. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. *Diabetes Care*. 2015 Mar;38(3):431-8.

**Cefalu WT**, Golden SH. Innovative approaches to understanding and addressing health disparities in diabetes care and research. *Diabetes Care*. 2015 Feb;38(2):186-8.

**Cefalu WT**, Nair KS, Seaquist ER, Zierath J, Boulton AJ, LeRoith D, Harrell RM, Grunberger G, Wartofsky L, Gore AC, Wierman ME, Hammes SR, Lange CA, Santen RJ. Statement of principle. *Horm Cancer*. 2015 Feb;6(1):1.

**Cefalu WT**. The "evidence" is in! It does get better! *Diabetes Care*. 2015 Jan;38(1):3-5

Henagan TM, **Cefalu WT**, Ribnicky DM, Noland RC, Dunville K, Campbell WW, Stewart LK, Forney LA, Gettys TW, Chang JS, Morrison CD. In vivo effects of dietary quercetin and quercetin-rich red onion extract on skeletal muscle mitochondria, metabolism, and insulin sensitivity. *Genes Nutr*. 2015 Jan;10(1):451.

Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Li W, Johnson J, Heymsfield SB, **Cefalu WT**, Ryan DH, Hu G. Body mass index and the risk of all-cause mortality among patients with type 2 diabetes mellitus. *Circulation*. 2014 Dec 9;130(24):2143-51.

**Cefalu WT**, Petersen MP, Ratner RE. The Alarming and Rising Costs of Diabetes and Pre-diabetes: A call for action! *Diabetes Care*. 2014 Dec;37(12):3137-8.

**Cefalu WT**, Nair KS, Seaquist ER, Zierath J, Boulton AJ, LeRoith D, Harrell RM, Grunberger G, Wartofsky L, Gore AC, Wierman ME, Hammes SR, Lange CA, Santen RJ. Statement of principle. *Endocr Rev*. 2014 Dec;35(6):850.

**Cefalu WT**, Nair KS, Seaquist ER, Zierath J, Boulton AJ, LeRoith D, Harrell RM, Grunberger G, Wartofsky L, Gore AC, Wierman ME, Hammes SR, Lange CA, Santen RJ. Statement of principle. *J Clin Endocrinol Metab*. 2014 Dec;99(12):4376.

Rosenstock J, **Cefalu WT**, Lapuerta P, Zambrowicz B, Ogbaa I, Banks P, Sands A. Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, in Type 2 Diabetes on Metformin Monotherapy. *Diabetes Care*. 2014 Sep 11. pii: DC\_140890 (In Press)

Zhao W, Katzmarzyk PT, Horswell R, Li W, Wang Y, Johnson J, Heymsfield SB, **Cefalu WT**, Ryan DH, Hu G. Blood pressure and heart failure risk among diabetic patients. *Int J Cardiol.* 2014 Sep;176(1):125-32

**Cefalu WT**, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, Raz I, Rosenstock J, Riddle MC. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. *Diabetes Care.* 2014 Sep;37(9):2647-59.

Leiter LA, **Cefalu WT**, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with a 28-Week Extension. *J Am Geriatr Soc.* 2014 62(7): 1252-62

**Cefalu WT**, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, Raz I, Rosenstock J, Riddle MC. Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management: Reflections from a *Diabetes Care* Editors' Expert Forum. *Diabetes Care* 2014; 37:1-13

**Cefalu WT**, Boulton AJM, Tamborlane WV, Moses RG, LeRoith D, Green EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry RR, Hill Golden S, Rich S, Reynolds L. Status of Diabetes Care: "It just doesn't get any better...or does it?" *Diabetes Care* July; 37 (7); 1782-1785

Home P, Riddle M, **Cefalu WT**, Bailey CJ, Bretzel RG, Del Prato S, Leroith D, Schernthaner G, van Gaal L, Raz I. Insulin therapy in people with type 2 diabetes: opportunities and challenges? *Diabetes Care.* 2014 Jun;37(6):1499-508.

Clark RV, Walker AC, O'Connor-Semmes RL, Leonard MS, Miller RR, Stimpson SA, Turner SM, Ravussin E, **Cefalu WT**, Hellerstein MK, Evans WJ Total body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humans. *J Appl Physiol* (1985). 2014 Jun 15;116(12):1605-13.

**Cefalu WT**, Tamborlane WV The artificial pancreas: are we there yet? *Diabetes Care.* 2014 May;37(5):1182-3.

Simon L, LeCapitaine N, Berner P, Vande Stouwe C, Mussell JC, Allerton T, Primeaux SD, Dufour J, Nelson S, Bagby GJ, **Cefalu W**, Molina PE. Chronic binge alcohol consumption alters myogenic gene expression and reduces in vitro myogenic differentiation potential of myoblasts from rhesus macaques. *Am J Physiol Regul Integr Comp Physiol.* 2014 Jun 1;306(11):R837-44.

**Cefalu WT.** A "spoonful of sugar" and the realities of diabetes prevention! *Diabetes Care.* 2014 Apr;37(4):906-8.

Vandanmagsar B, Haynie KR, Wicks SE, Bermudez EM, Mendoza TM, Ribnicky D, **Cefalu WT**, Mynatt RL *Artemisia dracunculus* L. extract ameliorates insulin sensitivity by attenuating inflammatory signalling in human skeletal muscle culture. *Diabetes Obes Metab.* 2014 Aug;16(8):728-38.

**Cefalu WT.** Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. *J Clin Invest.* 2014 Feb 3;124(2):485-7

**Cefalu WT,** Ratner RE The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: the "gift" that keeps on giving! *Diabetes Care.* 2014 Jan;37(1):5-7.

Zabaleta J, Velasco-Gonzalez C, Estrada J, Ravussin E, Pelligrino N, Mohler MC, Larson-Meyer E, Boulares AH, Powell-Young Y, Bennett B, Happel K, **Cefalu W,** Scribner R, Tseng TS, Sothorn M Inverse correlation of serum inflammatory markers with metabolic parameters in healthy, Black and White prepubertal youth. *Int J Obes (Lond).* 2014 Apr;38(4):563-8.

Kennedy BM, Katzmarzyk PT, Johnson WD, Griffin WP, Kennedy KB, **Cefalu WT,** Ryan DH Perceptions community residents have about partner institutions and clinical research. *Clin Transl Sci.* 2013 Dec;6(6):469-73.

Stenlöf K, **Cefalu WT,** Kim KA, Jodar E, Alba M, Edwards R, Tong C, Canovatchel W, Meininger G. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. *Curr Med Res Opin.* 2014 Feb;30(2):163-75.

Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Heymsfield SB, **Cefalu WT,** Ryan DH, Hu G. HbA1c and lower-extremity amputation risk in low-income patients with diabetes. *Diabetes Care.* 2013 Nov;36(11):3591-8.

**Cefalu WT,** Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. *Lancet.* 2013 Sep 14;382(9896):941-50.

**Cefalu WT.** "TODAY" reflects on the changing "faces" of type 2 diabetes. *Diabetes Care.* 2013 Jun;36(6):1732-4.

Bajpeyi S, Myrland CK, Covington JD, Obanda D, **Cefalu WT,** Smith SR, Rustan AC, Ravussin E. Lipid in skeletal muscle myotubes is associated to the donors' insulin sensitivity and physical activity phenotypes. *Obesity (Silver Spring).* 2014 Feb;22(2):426-34.

Katzmarzyk PT, Hu G, **Cefalu WT,** Mire E, Bouchard C The importance of waist circumference and BMI for mortality risk in diabetic adults. *Diabetes Care.* 2013 Oct;36(10):3128-30.

Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, **Cefalu WT,** Ryan DH, Hu G. Blood pressure and stroke risk among diabetic patients. *J Clin Endocrinol Metab.* 2013 Sep;98(9):3653-62.



Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JC, Leiter LA, Leroith D, DeFronzo R, **Cefalu WT**. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. *Diabetes Care*. 2013 Jun;36(6):1779-88

Wang ZQ, Zhang XH, Yu Y, Tipton RC, Raskin I, Ribnicky D, Johnson W, **Cefalu WT**. Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway. *Metabolism*. 2013 Sep;62(9):1239-49.

**Cefalu WT**, Rosenstock J, Henry RR, Riddle M. Signals and noise in drug safety analyses: the incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance. *Diabetes Care*. 2013 Jul;36(7):1804-6.

Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Li W, Johnson J, Heymsfield SB, **Cefalu WT**, Ryan DH, Hu G. Aggressive blood pressure control increases coronary heart disease risk among diabetic patients. *Diabetes Care*. 2013 Oct;36(10):3287-96.

Reading CL, Stickney DR, Flores-Riveros J, Destiche DA, Ahlem CN, **Cefalu WT**, Frincke JM. A synthetic anti-inflammatory sterol improves insulin sensitivity in insulin-resistant obese impaired glucose tolerance subjects. *Obesity (Silver Spring)*. 2013 Sep;21(9):E343-9.

Lapuerta P, Rosenstock J, Zambrowicz B, Powell DR, Ogbaa I, Freiman J, **Cefalu WT**, Banks P, Frazier K, Kelly M, Sands A. Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy. *Clin Cardiol*. 2013 Jul;36(7):367-71.

Obanda DN, **Cefalu WT**. Modulation of Cellular Insulin signaling and PTP1B effects by lipid metabolites in skeletal muscle cells. *Journal of Nutritional Biochemistry* (2013) In Press.

Kirk-Ballard H, Wang ZQ, Acharya P, Zhang XH, Yu Y, Kilroy G, Ribnicky D, **Cefalu WT**, Floyd E. An extract of *Artemisia dracuncululus* L. inhibits ubiquitin-proteasome activity and preserves skeletal muscle mass in a murine model of diabetes. *PLoS One* (2013) In Press

**Cefalu WT**. *Diabetes Care*: "state of the union". *Diabetes Care*. 2013 Jan;36(1):1-3.

Heymsfield SB, **Cefalu WT**. Does body mass index adequately convey a patient's mortality risk? *JAMA*. 2013 Jan 2;309(1):87-8

Stenlöf K, **Cefalu WT**, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. *Diabetes Obes Metab*. 2012 Dec 26. doi: 10.1111/dom.12054. [Epub ahead of print]

**Cefalu WT**. Kirkman MS. "New twist" in *Diabetes Care* for HbA(1c) reporting: "it takes two to tango"! *Diabetes Care*. 2012 Dec;35(12):2415-6.

Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, Cooksey RC, Gabrielsen D, Adams TD, Hunt SC, Hopkins PN, **Cefalu WT**, McClain DA. Adipocyte iron regulates adiponectin and insulin sensitivity. *J Clin Invest*. 2012 Oct 1;122(10):3529-40.

**Cefalu WT**. Progress to date for Diabetes Care; going mobile and putting information at your fingertips! *Diabetes Care*. 2012 Jul;35(7):1397-8.

Raz I, Amiel SA, Alberti G, Shehadeh N, Del Prato S, Zimmet P, **Cefalu WT**. Global call for free academic movement for international dialogue. *Diabetes Care*. 2012 Aug;35(8):1631-2.

Wang ZQ, Yu Y, Zhang XH, Floyd ZE, Boudreau A, Lian K, **Cefalu WT**. Comparing the effects of nano-sized sugarcane fiber with cellulose and psyllium on hepatic cellular signaling in mice. *Int J Nanomedicine*. 2012;7:2999-3012. Epub 2012 Jun 18.

Tam CS, Xie W, Johnson WD, **Cefalu WT**, Redman LM, Ravussin E. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. *Diabetes Care*. 2012 Jul;35(7):1605-10.

**Cefalu WT**. American diabetes association-European association for the study of diabetes position statement: due diligence was conducted. *Diabetes Care*. 2012 Jun;35(6):1201-3.

Liu AG, Most MM, Brashear MM, Johnson WD, **Cefalu WT**, Greenway FL Reducing the Glycemic Index or Carbohydrate Content of Mixed Meals Reduces Postprandial Glycemia and Insulinemia Over the Entire Day but Does Not Affect Satiety. *Diabetes Care*. 2012; Aug;35(8): 1633-7

Stull AJ, Wang ZQ, Zhang XH, Yu Y, Johnson WD, **Cefalu WT**. Skeletal Muscle Protein Tyrosine Phosphatase 1B Regulates Insulin Sensitivity in African Americans. *Diabetes*. 2012 Jun;61(6):1415-22.

**Cefalu WT**. Steps toward the meaningful translation of prevention strategies for type 2 diabetes. *Diabetes Care*. 2012 Apr;35(4):663-5.

Scherp P, Putluri N, Leblanc GJ, Wang ZQ, Zhang XH, Yu Y, Ribnicky D, **Cefalu WT**, Kheterpal I. Proteomic analysis reveals cellular pathways regulating carbohydrate metabolism that are modulated in primary human skeletal muscle culture due to treatment with bioactives from *Artemisia dracunculus* L. *J Proteomics*. 2012 Jun 18;75(11):3199-210. Epub 2012 Mar 26. PMID: PMC3367113

Gupta AK, Ravussin E, Johannsen DL, Stull AJ, **Cefalu WT**, and Johnson WD. Endothelial Dysfunction: An Early Cardiovascular Risk Marker in Asymptomatic Obese Individuals with Prediabetes *British Journal of Medicine & Medical Research* 2(3): 413-423, 2012

Obanda DN, Hernandez A, Ribnicky D, Yu Y, Zhang XH, Wang ZQ, **Cefalu WT**. Bioactives of *Artemisia dracunculus* L. mitigate the role of ceramides in attenuating insulin signaling in rat skeletal muscle cells. *Diabetes*. 2012 Mar;61(3):597-605. PMID: PMC3282822

Bennett B, Larson-Meyer DE, Ravussin E, Volaufova J, Soros A, **Cefalu WT**, Chalew S, Gordon S, Smith SR, Newcomer BR, Goran M, Sothorn M. Impaired insulin sensitivity and elevated ectopic fat in healthy obese vs. nonobese prepubertal children. *Obesity* (Silver Spring). 2012 Feb;20(2):371-5.

Wang ZQ, Zhang XH, Yu Y, Poulev A, Ribnicky D, Floyd ZE, **Cefalu WT**. Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet-fed mice. *J Nutr Biochem*. 2011 Nov;22(11):1064-73. PMID: PMC3135761

**Cefalu WT**. Fractalkine: A cellular link between adipose tissue inflammation and vascular pathologies. *Diabetes* 2011 (In Press)

**Cefalu WT**. Evolving treatment strategies for the management of type 2 diabetes. *Am J Med Sci*. 2012 Jan;343(1):21-6. Review.

LeCapitaine NJ, Wang ZQ, Dufour JP, Potter BJ, Bagby GJ, Nelson S, **Cefalu WT**, Molina PE. Disrupted anabolic and catabolic processes may contribute to alcohol-accentuated SAIDS-associated wasting. *J Infect Dis*. 2011 Oct 15;204(8):1246-55.

Buehrer BM, Duffin DJ, Lea-Currie UR, Ribnicky D, Raskin I, Stephens JM, **Cefalu WT**, Gimble JM. Screening of a botanical extract library using subcutaneous and visceral human adipose-derived stem cell based assays: Tools for the identification of nutritional agents impacting the metabolic syndrome. *J Nutr Biochemistry* 2011 (In Press)

Plaisance EP, Greenway FL, Boudreau A, Hill KL, Johnson WD, Krajcik RA, Perrone CE, Orentreich N, **Cefalu WT**, Gettys TW. Dietary Methionine Restriction Increases Fat Oxidation in Obese Adults with Metabolic Syndrome. *JECM* 2011 May;96(5):E836-40.

Anunciado-Koza RP, Zhang J, Ukropec J, Bajpeyi S, Koza RA, Rogers RC, **Cefalu WT**, Mynatt RL, Kozak LP. Inactivation of the mitochondrial carrier SLC25A25 (ATP-MG2+Pi transporter) reduces physical endurance and metabolic efficiency in mice. *J Biol Chem*. 2011 Apr 1;286(13):11659-71

Krishnapuram R, Dhurandhar EJ, Dubuisson O, Kirk-Ballard H, Bajpeyi S, Butte NF, Sothorn MS, Larsen-Meyer E, Chalew S, Bennett B, Gupta AK, Greenway FL, Johnson WD, Brashear M, Reinhart G, Rankinen T, Bouchard C, **Cefalu WT**, Ye J, Javier R, Zuberi A, Dhurandhar NV. A Template to Improve Glycemic Control without Reducing Adiposity or Dietary Fat. *Am J Physiol Endocrinol Metab*. 2011 May;300(5):E779-89.

Larson-Meyer DE, Newcomer BR, Ravussin E, Volaufova J, Bennett B, Chalew S, **Cefalu WT**, Sothorn M. Intrahepatic and intramyocellular lipids are determinants of insulin resistance in prepubertal children. *Diabetologia*. 2010 Dec 23.

Ilnytska O, Stütz AM, Park-York M, York DA, Ribnicky DM, Zuberi A, **Cefalu WT**, Argyropoulos G. Molecular mechanisms for activation of the agouti-related protein and stimulation of appetite. *Diabetes*. 2011 Jan;60(1):97-106.

Stull AJ, Cash KC, Johnson WD, Champagne CM, **Cefalu WT**. Bioactives in Blueberries Improve Insulin Sensitivity in Obese, Insulin-Resistant Men and Women. *J Nutr*. 2010 Oct;140(10):1764-8.

Graf BL, Raskin I, **Cefalu WT**, Ribnicky DM Plant-derived therapeutics for the treatment of metabolic syndrome. *Curr Opin Investig Drugs*. 2010 Oct;11(10):1107-15.

**Cefalu WT**. Translating "Nondiabetic" A1C levels to clinical practice: the art of medicine. *Diabetes*. 2010 Aug;59(8):1868-9.

Wang ZQ, Zhang XH, Yu Y, Poulev A, Ribnicky D, **Cefalu WT**. Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet fed mice. *J Nutr Biochem*. 2011 Jan;22(1):71-8.

Melendez-Ramirez LY, Richards RJ, **Cefalu WT**. Complications of type 1 diabetes. *Endocrinol Metab Clin North Am*. 2010 Sep;39(3):625-40.

Civitarese AE, MacLean PS, Carling S, Kerr-Bayles L, McMillan RP, Pierce A, Becker TC, Moro C, Finlayson J, Lefort N, Newgard CB, Mandarino L, **Cefalu W**, Walder K, Collier GR, Hulver MW, Smith SR, Ravussin E. Regulation of skeletal muscle oxidative capacity and insulin signaling by the mitochondrial rhomboid protease PARL. *Cell Metab*. 2010 May 5;11(5):412-26.

Wang ZQ, Yu Y, Zhang ZH, Floyd E and **Cefalu WT**. Adenovirus 36 decreases fatty acid oxidation and increases de novo lipogenesis in primary cultured human skeletal muscle cells by promoting Cidec/FSP27 Expression. *Int J of Obesity* (2010) (In Press)

Wang ZQ, **Cefalu WT**. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. *Curr Diab Rep*. 2010 Apr;10(2):145-51

Stull AJ, Galgani JE, Johnson WD, **Cefalu WT**. The Contribution of Race and Diabetes Status to Metabolic Flexibility in Humans. *Metabolism* 2010, 59(9): 1358-64.

Wang ZQ, Ribnicky DM, Zhang XH, Zuberi A, Raskin I, Yu U, **Cefalu WT**. An Extract of *Artemisia dracunculus* L. Enhances Insulin Receptor Signaling and Modulates Gene Expression in Skeletal Muscle in KKa<sup>y</sup> Mice. *J Nutr Biochem*. 2011 Jan;22(1):71-8.

**Cefalu WT**. The physiologic Role of Incretin Hormones: Clinical Applications. *J. Am Osteopath Assoc*. 2010, 110 (3 Suppl 2): S8-s14

Kheterpal I, Coleman L, Ku G, Wang ZQ, Ribnicky D, **Cefalu WT**. Regulation of insulin action by an extract of *Artemisia dracunculus* L. in primary human skeletal muscle culture – a proteomics approach. *Phytother Res* 2010 (In Press).

Anton SD, Martin CK, Han H, Coulon S, **Cefalu WT**, Geiselman P, Williamson DA. Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels. *Appetite* 2010, 55(1): 37-43.

**Cefalu WT**, Rood J, Pinsonat P, Qin J, Sereda O, Levitan L, Anderson R, Zhang XH, Martin C, Wang ZQ, Newcomer B. Characterization of the Metabolic and Physiologic Response from Chromium Supplementation in Subjects with Type 2 Diabetes. *Metabolism* 2010; 59(5): 755-62.

Hollander PA, **Cefalu WT**, Mitnick M, Lawrence D, Rosenstock J. Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetes. *Diabetes Technol Ther.* 2010 Mar;12(3):185-91.

Vilsbøll T, Rosenstock J, Yki-Järvinen H, **Cefalu WT**, Chen Y, Luo E, Musser B, Andryuk PJ, Ling Y, Kaufman KD, Amatruda JM, Engel SS, Katz L. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. *Diabetes Obes Metab.* 2010 Feb;12(2):167-77

**Cefalu WT**, Ribnicky D. Modulation of insulin action by botanical therapeutics. *Obes Weight Manag* 2009;5(6): 277-281.

**Cefalu WT**, Richards RJ, Melendez-Ramirez LY. Redefining treatment success in Type 2 diabetes: Comprehensive targeting of core defects. *Cleveland Clinic Journal of Medicine* 76 (Supplement 5): S39-S47, 2009

Rosenstock J, **Cefalu WT**, Hollander PA, Klioze SS, Reis J, Duggan WT. Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial. *Diabetes Technol Ther.* 2009;11(11):697-705.

Buse JB, Caprio S, **Cefalu WT**, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips GL 2nd, Robertson RP, Rubino F, Kahn R, Kirkman MS. How do we define cure of diabetes? *Diabetes Care.* 2009 Nov;32(11):2133-5.

**Cefalu WT**. Diabetes: HOME reveals new data on a cornerstone of treatment. *Nat Rev Endocrinol.* 2009;5(9):478-9

**Cefalu WT**. Primary prevention of type 2 diabetes: there are no simple solutions! *Diabetes.* 2009; 58(8):1730-1

Tompkins CL, **Cefalu W**, Ravussin E, Goran M, Soros A, Volaufova J, Vargas A, Sothorn MS. Feasibility of intravenous glucose tolerance testing prior to puberty. *Int J Pediatr Obes.* 2009 Jul 4:1-5.

**Cefalu WT**. Mortality and Glycemic Targets in the ICU: Another Paradigm Shift? *Diabetes* 2009; 58(7): 1469-70

Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, **Cefalu WT**, Ye J. Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice. *Diabetes.* 2009; 58(7): 1509-17

Wang ZQ, Floyd E, Qin J, Liu X, Yu Y, Zhang XH, Wagner JD, **Cefalu WT**. Modulation of skeletal muscle insulin signaling with chronic caloric restriction in cynomolgus monkeys. *Diabetes*. 2009; 58(7): 1488-98

Bray GA, Bouchard C, Church TS, **Cefalu WT**, Greenway FL, Gupta AK, Kaplan LM, Ravussin E, Smith SR, Ryan DH. Is it Time to Change the Way We Report and Discuss Weight Loss? *Obesity (Silver Spring)*. 2009; 17(4):619-21.

**Cefalu WT**. Inflammation, insulin resistance, and type 2 diabetes: back to the future? *Diabetes*. 2009;58(2):307-8.

Stewart LK, Wang Z, Ribnicky D, Soileau JL, **Cefalu WT**, Gettys TW. Failure of dietary quercetin to alter the temporal progression of insulin resistance among tissues of C57BL/6J mice during the development of diet-induced obesity. *Diabetologia*. 2009;52(3):514-23.

Kizelsztejn P, Govorko D, Komarnytsky S, Evans A, Wang Z, **Cefalu WT**, Raskin I. 20-Hydroxyecdysone decreases weight and hyperglycemia in a diet-induced obesity mice model. *Am J Physiol Endocrinol Metab*. 2009;296(3):E433-9.

Ribnicky DM, Kuhn P, Poulev A, Logendra S, Zuberi A, **Cefalu WT**, Raskin I. Improved absorption and bioactivity of active compounds from an anti-diabetic extract of *Artemisia dracuncululus* L. *Int J Pharm*. 2009 Mar 31;370(1-2):87-92.

**Cefalu WT**, Bohannon NJ, Fineberg SE, Teeter JG, Schwartz PF, Reis JM, Krasner AS. Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of continuous therapy. *Curr Med Res Opin*. 2008 (September)

Horton E, **Cefalu WT**, Haines ST, Siminerio LM. Multidisciplinary interventions: mapping new horizons in diabetes care. *Diabetes Educ*. 2008; 34 Suppl 4:78S-89S.

Kahn SE, **Cefalu WT**. Glucose control, macro- and microvascular disease, and the Food and Drug Administration: let's keep our eye on the ball. *J Clin Endocrinol Metab* 2008;93(10):3727-9.

Anton SD, Morrison CD, **Cefalu WT**, Martin CK, Coulon S, Geiselman P, Han H, White CL, Williamson DA. Effects of chromium picolinate on food intake and satiety. *Diabetes Technol Ther*. 2008; 10(5):405-12.

Stewart LK, Soileau JL, Ribnicky D, Wang ZQ, Raskin I, Poulev A, Majewski M, **Cefalu WT**, Gettys TW. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. *Metabolism* 2008;57(7 Suppl 1):S39-46.

**Cefalu WT**. Glycemic Targets and Cardiovascular Disease. *N Engl J Med*. 2008; 358(24):2633-5.

**Cefalu WT**, Brantley PJ. Botanicals and Cardiometabolic Risk: Positioning Science to Address the Hype. *Metabolism* 2008; 57(7): S1-2

Rogers PM, Mashtalir N, Rathod MA, Wang Z, Babin S, Gupta, Markward N, **Cefalu WT**, Dhurandhar NV. Metabolically Favorable Remodeling of Human Adipose Tissue by Human Adenovirus Ad-36. *Diabetes* 2008; 57(9): 2321-31.

Rosenstock J, **Cefalu WT**, Hollander PA, Belanger A, Eliaschewitz FG, Gross JL, Klioze SS, Aubin LB, Foyt H, Ogawa M, Duggan WT. Two-Year Pulmonary Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients with Type 2 Diabetes. *Diabetes Care*. 2008; 31(9): 1723-8.

Wang ZQ, **Cefalu WT**, Zhang XH, Yu Y, Qin J, Son L, Rogers PM, Ye J, Dhurandhar NV. Human adenovirus type 36 enhances glucose uptake in diabetic and non-diabetic human skeletal muscle cells independent of insulin signaling. *Diabetes* 2008; 57(7): 1805-13

**Cefalu WT**, Watson K. Intensive Glycemic Control and Cardiovascular Disease Observations from the ACCORD study: Now what can a clinician possibly think? *Diabetes* 2008; 57(5):1163-5.

**Cefalu WT**. Diabetic dyslipidemia and the metabolic syndrome. *Diab Met Syndr Clin Res Rev* 2008 2(3): 208-222.

**Cefalu WT**, Ye J, Wang ZQ Efficacy of Dietary Supplementation with Botanicals on Carbohydrate Metabolism in Humans. *Endocr Metab Immune Disord Drug Targets*. 2008; 8(2):78-81.

Kirk H, **Cefalu WT**, Ribnicky D, Liu Z, Eilertsen KJ. Botanicals as Epigenetic Modulators for Mechanisms Contributing to Development of Metabolic Syndrome. *Metabolism* 2008; 57(7): S16-23.

Wang ZQ, Zhang X, Ribnicky DM, Raskin I, **Cefalu WT**. Bioactives of *Artemisia dracuncululus* L. enhance cellular insulin signaling in primary human skeletal muscle culture. *Metabolism* 2008; 57(7 Suppl 1): S 58-64.

**Cefalu WT**, Mathieu C, Davidson J, Freemantle N, Gough S, Canovatchel B, on behalf of the OPTIMIZE Coalition. Patients' Perceptions of Subcutaneous Insulin in the OPTIMIZE Study: A Multicenter Follow-up Study. *Diabetes Technology and Therapeutics* 2008 10(1):25-38.

Floyd EZ, Wang ZQ, Kilroy G, **Cefalu WT**. Modulation of PPAR $\alpha$  Stability and Transcriptional Activity in Adipocytes by Resveratrol. *Metabolism* 2008; 57(7): S32-8.

Schmidt B, Ribnicky DM, Poulev A, Logendra S, **Cefalu WT**, and Raskin I. A Natural History of Botanical Therapeutics. *Metabolism* 2008; 57(7): S3-9.

Yin, J, Zuberi A, Gao Z, Liu D, Liu Z, Cefalu WT, Ye J. Effect of Shilianhua Extract and its Fractions on Body Weight of Obese Mice. *Metabolism* 2008; 57(7 Supple1): S47-51.

Barnes S, Birt DF, Cassileth B, **Cefalu W**, Chilton S, Farnsworth N, Raskin I, van Breeman R, Weaver CM. Technologies and experimental approaches at the National Institutes of Health Botanicals Research Centers. *Am J Clin Nutr*. 2008 87(2):476S-80S.

Ribnicky DM, Poulev A, Schmidt B, **Cefalu WT**, Raskin I. Evaluation of Botanicals for Improving Human Health. *Am J Clin Nutr.* 2008 87(2):472S-5S.

**Cefalu WT**, Ye J, Zuberi A, Ribnicky D, Raskin I, Liu Z, Wang ZQ, Brantley PJ, Howard L, Lefevre M. Botanicals and Metabolic Syndrome. *Am J Clin Nutr.* 2008 87(2):481S-7S.

Burns Kraft TF, Dey M, Rogers RB, Ribnicky DM, Gipp DM, **Cefalu WT**, Raskin I, AND Lila MA Phytochemical Composition and Metabolic Performance Enhancing Activity of Dietary Berries Traditionally Used by Native North Americans. *J Agric Food Chem.* 2008 13;56(3):654-60.

Govorko D, Logendra S, Wang Y, Ribnicky D, Poulev A, **Cefalu WT** and Raskin I. Polyphenolic Compounds from *Artemisia dracuncululus* L. Inhibit PEPCK Gene Expression and Gluconeogenesis in an H4IIE Hepatoma Cell Line. *Am J Physiol Endocrinol Metab.* 2007 293(6):E1503-10.

**Cefalu WT**, Urquhart S. Clinical management Strategies for type 2 diabetes. *JAAPA.* 2007 Dec;Suppl:9-14.

Wang ZQ, Qin J, Martin J, Zhang XH, Sereda O, Anderson R, Pinsonat P, **Cefalu WT**. Phenotype of Subjects with Type 2 Diabetes May Determine Clinical Response to Chromium Supplementation. *Metabolism* 2007, 56(12): 1635-42.

Wang ZQ, Zuberi A, Zhang XH, MacGowan J, Qin J, Ye X, Son L, Wu Q, Lian K, **Cefalu WT**. Effects of Dietary Fibers on Weight Gain, Carbohydrate Metabolism and Gastric Ghrelin Gene Expression in High Fat Diet Fed Mice. *Metabolism*2007, 56(12): 1652-5.

American Diabetes Association Statement on Emergency and Disaster Preparedness A report of the Disaster Response Task Force. \*The Disaster Response Task Force. \*[Fonseca VA (Chair), Bennett MV, Booker B, **Cefalu WT**, Clark N, Deeb LC, Hamm LL, McDuffie R, Samorian HD, Strange P, Tuncer D, Wosahla S]. *Diabetes Care* 2007, 30 (9): 2395-98.

**Cefalu WT**. Clinical Research Observations with Use of Human Inhaled Insulin (Exubera) in Patients with Type 1 and 2 Diabetes. *Diabetes Technology and Therapeutics*, 2007 9 (Suppl 1):S28-40.

**Cefalu WT**. The New Diabetes Inhalers. New Tools for the Clinician. *Current Diabetes Reports*, 2007 7(3):165-7.

**Cefalu WT**. Pharmacotherapy for Treatment of Patients with Type 2 Diabetes: Rationale and Specific Agents. *Clinical Pharmacology and Therapeutics*, 2007, 81(5):636-49.

**Cefalu WT**. Point: Pulmonary inhalation of insulin: another "brick in the wall". *Diabetes Care.* 2007, 30(2):439-41.

Norwood P, Dumas R, **Cefalu W**, Yale JF, England R, Riese R, Teeter J. Randomized Study to Characterize Glycemic Control and Short-Term Pulmonary Function in Patients with Type 1 Diabetes Receiving Inhaled Human Insulin (Exubera(R)). *J Clin Endocrinol Metab.* 2007, 92(6): 2211-4.



Ptitsyn A, Hulver M, **Cefalu W**, York D, Smith SR. Unsupervised clustering of gene expression data points at hypoxia as possible trigger for metabolic syndrome. *BMC Genomics*. 2006 Dec 19;7:318.

Martin J, Matthews D, **Cefalu WT**. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes: response to Mark. *Diabetes Care*. 2006 Dec;29(12):2764-5.

**Cefalu WT**. Bariatric surgery: part of the answer to the obesity epidemic. *Cleve Clin J Med*. 2006 Nov;73(11):969-70.

Morrison CD, White CL, Wang Z, Lee SY, Lawrence DS, **Cefalu WT**, Zhang ZY, Gettys TW. Increased hypothalamic protein tyrosine phosphatase 1B contributes to leptin resistance with age. *Endocrinology*. 2007 Jan;148(1):433-40.

Gao Z, Wang Z, Zhang X, Butler AA, Zuberi A, Gawronska-Kozak B, Lefevre M, York D, Ravussin E, Berthoud HR, McGuinness O, **Cefalu WT**, Ye J. Inactivation of PKC $\theta$  leads to increased susceptibility to obesity and dietary insulin resistance in mice. *Am J Physiol Endocrinol Metab*. 2007 292(1):E84-91.

Martin J, Wang ZQ, Wachtel D, Volaufova J, Matthews DE, **Cefalu, WT**. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. *Diabetes Care*. 2006 Aug; 29(8): 1826-1832.

**Cefalu WT**. Animal Models of Type 2 Diabetes: Clinical Presentation and Pathophysiological Relevance to the Human Condition. *ILAR J* 2006;47(3):186-98

Wang ZQ, Zhang XH, Russell JC, Hulver M, **Cefalu WT**. Chromium Picolinate Enhances Skeletal Muscle Cellular Insulin Signaling In Vivo in Obese, Insulin-Resistant JCR:LA-cp Rats. *J Nutr*. 2006 Feb;136(2):415-20.

**Cefalu WT**, Glycemic control and cardiovascular disease--should we reassess clinical goals? *N Engl J Med*. 2005 Dec 22;353(25):2707-9.

**Cefalu WT**, Smith SR, Blonde L, Fonseca V. The Hurricane Katrina Aftermath and Its Impact on Diabetes Care: Observations from "ground zero": lessons in disaster preparedness of people with diabetes. *Diabetes Care*. 2006 Jan; 29(1):158-60.

Mellen PB, **Cefalu W**, Herrington DM. Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women. *Arteriosclerosis, Thrombosis and Vascular Biology* 2006 Jan;26(1):189-93.

Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan S-P, **Cefalu WT**. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes. A randomized, controlled trial. *Ann Intern Med* 2005; 143: 549-558.

Ribnicky DM, Poulev A, Watford M, **Cefalu WT**, Raskin I. Antihyperglycemic Activity of TARRALIN™, an Ethanolic Extract of *Artemisia dracuncululus* L. *Phytomedicine*, 2006 Sep;13(8):550-7.

Cefalu CA, **Cefalu WT**. Controlling hypoglycemia in Type 2 diabetes: Which agent for which patient? *Fam Prac* 54(10): 855-62, 2005.

DeFronzo RA, Bergenstal RM, **Cefalu WT**, Pullman J, Lerman S, Bode BW, Phillips LS; Exubera Phase III Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. *Diabetes Care* 28(8): 1922-8, 2005.

Feinglos M, Dailey G, **Cefalu W**, Osei K, Tayek J, Canovatchel W, Chaiken R, Kourides I. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. *Diabetes Res Clin Pract* 2005; 68(2): 167-75.

Jovanovic L, Knopp RH, Kim H, **Cefalu WT**, Zhu XD, Lee YJ, Simpson JL, Mills JL. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. *Diabetes Care* 28(5): 1113-7, 2005.

**Cefalu WT**: Economics of diabetes-cost impact of not treating diabetes early and intensively. *Clin Cornerstone*. 2004;6(2):51-60.

**Cefalu WT**, Hu F: Role of Chromium in Human Health and in Diabetes. *Diabetes Care* 2004; 27(11): 2741-51.

**Cefalu WT**, Wang ZQ, Collins J, Bell-Farrow AD, Wagner JD: Caloric Restriction and Cardiovascular Aging in Cynomolgus Monkeys (*Macaca fascicularis*): Metabolic, Physiologic and Atherosclerosis Measures from a 4 year Intervention Trial. *J. Gerontol* 59(10): 1007-14, 2004.

Fonseca VA, Kelly DE, **Cefalu WT**, Baron MA, Purkayastha D, Nestler JE, Hsia S, Gerich JE. Hypoglycemic potential of nateglinide versus glyburide in patients with Type 2 diabetes mellitus. *Metabolism* 53(10): 1331-5, 2004.

**Cefalu WT**, Wang, ZQ, Schneider DJ, Absher, PM, Baldor LC, Taatjes D, Sobel BE. Effects of insulin sensitizers on plaque vulnerability associated with elevated lipid content in atheroma in ApoE-knockout mice. *Acta Diabetol* 2004 Mar; 41(1):25-31.

Edwards, IJ, Wagner, JD, Vogl-Willis, CA, Litwak, KN. **Cefalu WT**. Arterial heparin sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys. *Cardiovascular Diabetology* 29;3(1): 6 2004.

**Cefalu WT**. Evolving Strategies for Insulin Delivery and Therapy. *Drugs* 64(11): 1149-61, 2004.

**Cefalu WT**. Concept, Strategies, and Feasibility of Non-Invasive Insulin Delivery. *Diabetes Care* 27: 239-246, 2004.

Grunberg SM, **Cefalu WT**. The Integral Role of Clinical Research in Clinical Care. *N Engl J Med*. 348(14): 1386-8, 2003.

**Cefalu WT**, Leroith D. Overcoming the Barriers for Achieving Standards of Diabetes Care: The formation of CADRE. *Diabetes Technol Thera.* 2003;5:385-392.

**Cefalu WT**: Optimizing Glycemic Control: The Search for Feasible Non-invasive Insulin Delivery Systems. *C J Diabetes.* 2003;27(1):42-51.

**Cefalu, WT**, Schneider, DJ, Carlson, HE, Migdal, P, et al. Effect of Combination Glipizide GITS/ Metformin on Fibrinolytic and Metabolic Parameters in Poorly Controlled Type 2 Diabetic Subjects. *Diabetes Care* 25:2123-2128, 2002.

Bindra S., **Cefalu WT**. Alternative Approaches to Subcutaneous Insulin Injections. *Curr Opin Endocrinol Diab.* 2002, 9:338-341.

**Cefalu WT**: Evaluation of Alternative Strategies for Optimizing Glycemia: Progress to Date. *American Journal of Medicine* 2002; 113(6A):23S-35S.

Edwards IJ, Terry JG, Bell-Farrow AD, **Cefalu WT**. Improved Glucose Control Decreases the Interaction of Plasma Low Density Lipoproteins with Arterial Proteoglycans. *Metabolism* 2002 Oct;51(10):1223-9.

Bindra S, **Cefalu WT**. Exubra Inhale Therapeutic Systems. *Curr Opin Investig Drugs.* 2002; 3(5): 758-62.

**Cefalu WT**, Wang ZQ, Zhang XH, Baldor LC, Russell JC. Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic [JCR-LA Corpulent] rats. *J Nutr* 2002; 132(6): 1107-14.

Carter CS, Ramsey MM, Ingram RL, Cashion AB, **Cefalu WT**, Wang ZQ, Sonntag WE. Models of growth hormone and IGF-1 deficiency: Applications to studies of aging processes and lifespan determination. *J Gerontol A Biol Sci* 2002; 57(5): B177-88.

Cappelleri JC, **Cefalu WT**, Rosenstock J, Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. *Clin Ther* 2002 24:552-564.

Bindra S, Rosenstock J, **Cefalu WT**. Inhaled insulin: a novel route for insulin delivery. *Expert Opin Inv Drug* 2002 11:687-691.

Joy MS, **Cefalu WT**, Hogan SL, Nachman P. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. *Am J Kidney Dis* 2002; 39:297-307.

Toth MT, Sites CK, **Cefalu WT**, Matthews DE, Poehlman ET. Determinants of insulin-stimulated glucose disposal in middle-aged, premenopausal women. *Am J Physiol Endocrinol Metab.* 2001 Jul; 281(1):E113-21.

Poehlman ET, Turturro A, Bodkin N, **Cefalu, W**, Heymsfield S, Holloszy, Kemnitz J. Caloric restriction mimetics: physical activity and body composition changes. *J Gerontol Biol Sci* 2001; 56A(Special Issue I):45-54.

**Cefalu WT.** Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. *Ann Med* 2001; 33:579-586.

Edwards IJ, Rudel LL, Terry JG, Kemnitz JW, Weindruch R, Zaccaro DJ, **Cefalu WT.** Caloric restriction lowers plasma lipoprotein (a) in male but not female rhesus monkeys. *Exp Gerontol* 2001; 36:1413-1418.

**Cefalu WT.** The use of hormone replacement therapy in postmenopausal women with type 2 diabetes. *J Womens Health Gend Based Med* 2001; 10:241-255.

Wagner JD, Cline M, Shadoan MK, Bullock BC, Rankin SE, and **Cefalu WT.** Naturally occurring and experimental diabetes in cynomolgus monkeys: a comparison of carbohydrate and lipid metabolism and islet pathology. *Toxicol Pathol* 2001; 29:142-148.

**Cefalu WT.** Inhaled insulin: A proof-of-concept study. *Ann Intern Med* 2001; 134:795.

**Cefalu WT,** Skyler J, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand R, for the Inhaled Insulin Study Group. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. *Ann Intern Med* 2001; 134:203-207.

Skyler JS, **Cefalu WT,** Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA, for the Inhaled Insulin Phase II Study Group. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-of-concept study. *Lancet* 2001; 357:331-335.

**Cefalu WT.** Insulin resistance: Cellular and clinical concepts. *Exp Biol Med* 2001; 226:13-26.

**Cefalu WT,** Terry JG, Thomas MJ, Morgan TM, Edwards IJ, Rudel LL, Kemnitz JW, Weindruch R. In vitro oxidation of low density lipoprotein in two species of nonhuman primates subjected to caloric restriction. *J Gerontol A Biol* 2000; 55A:B355-B361.

**Cefalu WT,** Wang ZQ, Bell-Farrow AD, Sonntag W, Waite M. Chronic caloric restriction alters muscle membrane fatty acid content. *Exp Gerontol* 2000; 35:331-341.

**Cefalu WT.** Commentary on: "Effect of long-term caloric restriction on Glut-4, phosphatidylinositol-3 kinase p85 subunit, and insulin receptor substrate-1 protein levels in rhesus monkey skeletal muscle." *J Gerontol Biol Sci* 2000; 55A:B47-B48.

**Cefalu WT.** Modern-day management of type 2 diabetes. *Resident & Staff Physician* 2000; 46:10-22.

**Cefalu WT,** Wang ZQ, Redmon E, Bell-Farrow AD, McBride D, King, T. Clinical validity of a self-test fructosamine in outpatient diabetic management. *Diabetes Technol Thera* 1999; 1:435-441.

**Cefalu WT,** Wagner JD, Bell-Farrow AD, Edwards IJ, Terry JG, Weindruch R, Kemnitz JW. Influence of caloric restriction on the development of atherosclerosis in nonhuman primates: Progress to date. *Toxicol Sci* 1999; 52(Supp):49-55.

Sonntag WE, Lynch CD, **Cefalu WT,** Ingram RL, Bennett SA, Thornton PL, Khan AS.

Pleiotropic effects of growth hormone and insulin-like growth factor (IGF)-1 on biological aging: inferences from moderate caloric-restricted animals. *J Gerontol A Biol Sci Med Sci*. 1999; 54(12):B521-38.

Edwards IJ, Wagner JD, Litwak KN, Rudel LL, **Cefalu WT**. Glycation of plasma low density lipoproteins increases interaction with arterial proteoglycans. *Diab Res Clin Prac* 1999; 46:9-18.

Toffolo G, **Cefalu WT**, Cobelli C. Beta-cell function during insulin-modified intravenous glucose tolerance test successfully assessed by the C-peptide minimal model. *Metabolism* 1999; 48:1162-1166.

Farr AK, Braun RD, **Cefalu WT**, Bell-Farrow AD, Wang ZQ, Hatchell DL. Increased non-enzymatically glycosylated proteins in the vitreous humor of diabetic animals. *Lab Anim Sci* 1999; 49:58-61.

**Cefalu WT**, Bell-Farrow AD, Stegner J, Wang ZQ, King T, Morgan T, Terry JG. Effect of chromium picolinate on insulin sensitivity in vivo. *J Trace Elem Exp Med* 1999; 12:71-83.

Litwak KN, Cefalu WT, Wagner JD. Chronic hyperglycemia increases arterial low-density lipoprotein metabolism and atherosclerosis in cynomolgus monkeys. *Metabolism* 1998; 47:947-954.

Wagner JD, Thomas MJ, Williams JK, Zhang L, Greaves KA, **Cefalu WT**. Insulin sensitivity and cardiovascular risk factors in ovariectomized monkeys with estradiol alone or combined with norgestrel acetate. *J Clin Endocrinol Metab* 1998; 83:896-901.

Edwards IJ, Rudel LL, Terry JG, Kemnitz JW, Weindruch R, **Cefalu WT**. Caloric restriction in rhesus monkeys reduces low density lipoprotein interaction with arterial proteoglycans. *J Gerontol A Biol Sci Med Sci* 1998; 53:B443-B448.

Litwak KN, *Cefalu WT*, Wagner JD. Streptozotocin-induced diabetes mellitus in cynomolgus monkeys: changes in carbohydrate metabolism, skin glycation, and pancreatic islets. *Lab Anim Sci* 1998; 48:172-178.

**Cefalu WT**, Bell-Farrow AD, Wang ZQ, McBride D, Dalgleish D, Terry JG. Effect of Glipizide GITS on Insulin sensitivity, Glycemic Indices, and Abdominal Fat Composition in NIDDM. *Drug Development Research* 1998; 44:1-7.

**Cefalu WT**, Werbel SS, Bell-Farrow AD, Terry JG, Wang ZQ, Opara EC, Morgan T, Hinson W, Crouse JR. Insulin resistance and fat patterning with aging: relationship to metabolic risk factors for cardiovascular disease. *Metabolism* 1998, 47;4:401-408.

**Cefalu WT**, Wagner JD. Aging and atherosclerosis in both human and non-human primates. *AGE* 1997; 20:15-28.

Wagner JD, **Cefalu WT**, Anthony MS, Litwak KN, Zhang LI, Clarkson TB. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. *Metabolism Clin Exp* 1997; 46:698-705.

Wang ZQ, Bell-Farrow AD, Sonntag WE, **Cefalu WT**. Effect of age and caloric restriction on insulin receptor binding and glucose transporter levels in aging rats. *Exp Gerontology* 1997; 32:671-684.

**Cefalu WT**, Wagner JD, Wang ZQ, Bell-Farrow AD, Collins J, Bechtold R, Morgan T. A study of caloric restriction in cynomolgus monkeys (*Macaca fascicularis*): A potential model for aging research. *J Gerontology* January 1997;Vol 52A(1):B10-B19.

Wagner JD, Martino MA, Jayo MJ, Anthony MS, Clarkson TB, **Cefalu WT**. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. *Metabolism* 1996;45:1254-1262.

O'Brien D, Wagner JD, Litwak KN, Carlson CS, **Cefalu WT**, Jordan K, Johnson KH, Butler PC. Islet amyloid and islet amyloid polypeptide in cynomolgus macaques (*Macaca fascicularis*): An animal model of human non-insulin dependent diabetes mellitus. *Vet Pathol* 1996;33:479-485.

**Cefalu WT**. Treatment of type II diabetes: What options have been added to traditional methods? *Postgraduate Medicine* 1996;99(3):109-122.

**Cefalu WT**. Non-insulin dependent diabetes: Clinical considerations. *Clinician Reviews* 1996;6(3):69-87.

Wagner JD, Carlson CS, O'Brien TD, Anthony MS, Bullock BC, **Cefalu WT**. Diabetes mellitus and islet amyloidosis in cynomolgus monkeys. *Lab An Sci* 1996;46:36-41.

Wagner JD, Bagdade JD, Litwak KN, Zhang L, Bell-Farrow AD, Wang ZQ, **Cefalu WT**. Increased glycation of plasma lipoproteins in diabetic cynomolgus monkeys. *Lab An Sci* 1996;46:31-35.

Dominquez LJ, Weinberger MH, **Cefalu WT**, Jacobs DB, Barbagallo M, Walsh MF, Sowers JR. Doxazosin lowers blood pressure and improves insulin responses to a glucose load with no changes in tyrosine kinase activity or insulin binding. *Am J Hypertens* 1995;8:528-532.

**Cefalu WT**, Bell-Farrow AD, Wang ZQ, Sonntag WE, Fu MX, Baynes JW, Thorpe SR. Caloric restriction (CR) decreases age-dependent accumulation of the glycoxidation products N<sup>ε</sup>(Carboxymethyl)lysine (CML) and pentosidine (P) in rat skin. *J Gerontol: Biol Sci* 1995;50A(6):B337-B341.

**Cefalu WT**, Wang ZQ, Werbel SA, Bell-Farrow A, Crouse JR, Hinson WH, Terry JG, Anderson R. Contribution of visceral fat mass to the insulin resistance of aging. *Metabolism* 1995;44(7):954-959.

Berelowitz M, Fischette C, **Cefalu WT**, Schade DS, Sutfin T, Kourides IA. Comparative efficacy of a once-a-day controlled-release formulation of glipizide (glipizide GITS) and immediate-release glipizide in patients with non-insulin-dependent diabetes mellitus. *Diabetes Care* 1994;17:1460-1464.

Anderson RL, Hamman RF, Savage PJ, Saad MF, Laws A, Kades WW, Sands RE, **Cefalu WT**. Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT) tests: Insulin resistance atherosclerosis study (IRAS). *Amer J Epidem* 1995;142:724-732.

Usala AL, Madigan T, Burgera B, **Cefalu WT**, Sinha MK, Powell JG, Usala SJ. High dose intravenous, but not low dose subcutaneous, IGF-1 therapy induces sustained insulin sensitivity in severely resistant Type 1 diabetes mellitus. *J Clin Endo Metab* 1994;79:435-440.

**Cefalu WT**, Wang ZQ, Bell-Farrow AD, Kiger FD, Izlar C. Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. *Clin Chem* 1994;40:1317-1321.

**Cefalu WT**, Wagner JD, Bell-Farrow AD, Wang ZQ, Adams MR, Toffolo G, Cobelli C. Effects of hormone replacement therapy on insulin sensitivity in surgically post-menopausal cynomolgus monkeys. *Am J Obstet & Gynecol* 1994;171:440-445.

Jarrow JP, Kirkland J, Koritnik DR, **Cefalu WT**. Effect of obesity and fertility status upon sex steroid levels in men. *Urology* 1993;42:171-174.

**Cefalu WT**, Ettinger WH, Bell-Farrow AD, Thomas JL, Stat M. Serum fructosamine as a screening test for diabetes in the elderly. *J Am Geriatric Society* 1993;41:1090-1094.

**Cefalu WT**, Wagner JD, Bell-Farrow AD. Role of Glycated proteins in the detection and monitoring of diabetes in cynomolgus monkeys. *Lab Animal Sci* 1993;43:73-77.

**Cefalu WT**, Bell-Farrow AD, Petty M, Izlar C. Clinical validation of a new, 2nd generation fructosamine assay. *Clin Chem* 1991;37:1252-1256.

**Cefalu WT**, Bell-Farrow A, Wang ZQ, Ralapati S. Detection of furosine in biomedical samples using a novel and rapid high performance liquid chromatography system. *Carbohydrate Research* 1991;215:117-125.

**Cefalu WT**, Wang ZQ, Bell-Farrow A, Ralapati S. Liver and kidney tissue membranes as tissue markers for non-enzymatic glycation. *Diabetes* 1991;40:902-907.

**Cefalu WT**, Prather KL, Chester DL, Wheeler CJ, Biswas M, Pernoll ML. Total serum glycosylated proteins in detection and monitoring of gestational diabetes. *Diabetes Care* 1990;13:872-875.

Lupo MA, **Cefalu WT**, Pardridge WM. Kinetics of lactate transport into rat liver in vivo. *Metabolism* 1990;39:374-377.

**Cefalu WT**, Prather KL, Murphy WA. Clinical evaluation of a new, glycosylated serum protein assay (serum fructosamine) in outpatient monitoring of the elderly diabetic. *J Am Geriatr Soc* 1989;37:833-837.

**Cefalu WT**, Mejia E, Puente GR, Fleishacker D, Macaulay K. Correlation of serum fructosamine activity in type 1 diabetic children. *Am J Med Sci* 1989;297:244-246.

**Cefalu WT**. Understanding protein glycosylation. *Practical Diabetology* 1988;7:17-19.

**Cefalu WT**, Parker TB, Johnson CR. Validity of serum fructosamine as index of short-term glycemic control in diabetic outpatients. *Diabetes Care* 1988;11:662-664.

**Cefalu WT**, Pardridge WM. Augmented transport and metabolism of sex steroids in lymphoid neoplasia in the rat. *Endocrinology* 1987;120:1000-1009.

**Cefalu WT**, Pardridge WM, Chaudhuri G, Judd HL. Serum bioavailability and tissue metabolism of testosterone and estradiol in rat salivary gland. *J Clin Endocrinol Metab* 1986;63:20-28.

Steingold KA, **Cefalu W**, Pardridge W, Judd HL, Chaudhuri G. Enhanced hepatic extraction of estrogens used for replacement therapy. *J Clin Endocrinol Metab* 1986;62:761-766.

**Cefalu WT**, Pardridge W. Restrictive transport of a lipid-soluble peptide (cyclosporin) through the blood-brain barrier. *J Neurochem* 1985;45:1954-1956.

**Cefalu WT**, Pardridge WM, Premachandra BN. Hepatic bioavailability of thyroxine and testosterone in familial dysalbuminemic hyperthyroxinemia. *J Clin Endocrinol Metab* 1985;61:783-786.

Manni A, Pardridge WM, **Cefalu W**, Nisula BC, Bardin CW, Santner SJ, Santen RJ. Bioavailability of albumin-bound testosterone. *J Clin Endocrinol Metab* 1985;61:705-710.

Pardridge WM, Eisenberg J, **Cefalu WT**. Absence of albumin receptor on brain capillaries in vivo or in vitro. *Am J Physiol* 1985;249:E264-E267.

Frost P, Kerbel RS, Bauer E, Tartmella-Biondo R, **Cefalu W**. Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. *Cancer Res* 1983;43:125-132.

#### PUBLICATIONS LISTED AS STUDY INVESTIGATOR

Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P, Sosenko J, Atkinson M, Pugliese A, Oram RA; Type 1 Diabetes TrialNet Study Group. A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. *Diabetes Care*. 2018 Sep;41(9):1887-1894.



Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. *N Engl J Med*. 2015 Aug 13;373 (7):610-20.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. *Diabetes Care*. 2015 May;38 (5):940-2.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. *Diabetes*. 2013 Dec;62 (12):4179-83.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. *Diabetes Care*. 2013 Sep;36(9):2615-20.

Pop-Busui R, Lu J, Lopes N, Jones TL; BARI 2D Investigators. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. (Study Investigator). *J Peripher Nerv Syst*. 2009;14(1):1-13.

Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial (Study Investigator). *Lancet*. 2009;373(9662):473-81.

Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. (Study Investigator) *Am Heart J*. 2008; 156(3):528-536

#### JOURNAL SUPPLEMENTS: EDITOR

Cefalu WT. Botanicals and Cardiovascular Risk. *Metabolism: Clinical and Experimental*, Vol. 57, No 7, Suppl 1, 2008

Cefalu WT. Will using Exogenous Insulin Earlier in Disease Progression Prevent Vascular Disease in Diabetes? *American Journal of Medicine* 2002; 113(6A).

MONOGRAPHS (SENIOR EDITOR AND/OR AUTHOR)

Cefalu WT, Cefalu CA, Lipsky MS. Clinical Landmarks and Issues in Type 2 Diabetes; Cardiovascular Comorbidities. October 2003; Vol.1, No. 2

Cefalu WT, Cefalu CA, Lipsky MS. Clinical Landmarks and Issues in Type 2 Diabetes; Dual Defects: Preexisting and Progressive. October 2003; Vol.1, No. 2

Cefalu WT. Clinical Landmarks and Issues in Type 2 Diabetes; Complications: The Case for Tighter Glycemic Control. April 2003; Vol. 1, No 1.

Cefalu WT. Advances in Insulin Therapy: The Future of Diabetes Management. CME Notes in New Frontiers in Diabetes Management, Medical Education Group LLC, 2002.

Cefalu WT. Ischemic preconditioning and insulin secretagogues: Facts, myths, and speculations. CME Notes in Endocrinology; New York Medical College and QD Healthcare Group, New York, 2001.

Cefalu WT. Natural history of type 2 diabetes. In: Type 2 Diabetes: A Focus on Management with Insulin Secretagogues. CME Notes in Endocrinology; New York Medical College and QD Healthcare Group, New York, 2001.

Cefalu WT. The  $\beta$ -Cell in Type 2 Diabetes Mellitus: An Overview. CME Notes in Endocrinology; New York Medical College and QD Healthcare Group, NY, 2001.

Cefalu WT. Remission of Type 2 Diabetes Mellitus: Role of the  $\beta$ -Cell. CME Notes in Endocrinology; New York Medical College and QD Healthcare Group, NY, 2001.

Cefalu WT. Pathways Toward Optimal Management of Type 2 Diabetes Mellitus. CME Notes in Endocrinology; New York Medical College and QD Healthcare Group, NY, 2001.

Cefalu WT, Banerji MA, Blonde L, Hollander P. Restoring Balance to the Management of Type 2 Diabetes. QD Healthcare Group, Greenwich, CT, 2001.

ABSTRACTSABSTRACTS PRESENTED TO THE 76<sup>TH</sup> ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2016, NEW ORLEANS, LA)

Garg SK, Bode BW, Buse JB, Cefalu WT, Heptulla R, Rendell M, Rosenstock J, Banks PL, Lapuerta P, Sands AT, Zambrowicz BP, Strumph PS. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, Reduces Late but Not Early Postprandial Glucose Absorption in T1DM: Potential Implications for Recovery from Hypoglycemia. (Presented as poster presentation, 1078-P)

Hsia DS, Larrivee S, Cefalu WT, Johnson WD. Variability of HbA1c Cutoffs When Stratified by BMI in Screening for Prediabetes and Diabetes. (Presented as poster presentation 1418-P)

Greenway F, Guzman F, Tamayo RA, Kim SG, Watkins E, Moon MK, Rhee SY, Lee MK, Frias JP, Rosenstock J, Chung SY, Lee SH, Block B, Cha BS, Lee KW, Cefalu WT, Harper WL, Park HK, Kim BJ, Reaume AG, Yoo HW. Clinical Proof-of-Concept for an Antidiabetic Agent with a Novel Mechanism for Reducing Insulin Resistance. (Presented as a poster presentation 124-LB)

ABSTRACTS PRESENTED TO THE 75<sup>TH</sup> ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2015, BOSTON, MA)

Cefalu WT, Leiter LA, Johnsson E, Sugg J, Gause-Nilsson I. Long-term Safety and Efficacy of Dapagliflozin in Patients with T2DM and Cardiovascular Disease Receiving Loop Diuretics. (Presented as poster presentation, 1216-P)

Cefalu WT, Leiter LA, Johnsson E, Sugg J, Gause-Nilsson I. Safety and Efficacy of Dapagliflozin in Patients with T2DM and Cardiovascular Disease. (Presented as oral presentation, 106-OR)

ABSTRACTS PRESENTED TO THE 73<sup>RD</sup> ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2013, CHICAGO, IL)

Stenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, Tong C, Canovatchel W, Meininger G. Efficacy and Safety of Canagliflozin (CANA) Monotherapy in Subjects with Type 2 Diabetes (Presented as poster presentation, 1664-P)

Zhao W, Katmarzyk PT, Horwell R, Wang Y, Johnson J, Cefalu WT, Ryan DH, Hu G. Blood Pressure and Stroke Risk among Louisiana Diabetic Patients (Presented as poster presentation, 1409-P)

Wang ZO, Zhang XH, Yu Y, Ribnicky D, Cefalu WT. Effects of *Artemisia Dracunculus L.* Extract (Presented as poster presentation, 2259-P)

ABSTRACTS PRESENTED TO THE 72<sup>ND</sup> ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2012, PHILADELPHIA, PA)

Wang ZQ, Yu Y, Tipton RC, Zhang X, Ribnicky D, Cefalu WT. *Artemisia Scoparia* Extract Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High-Fat-Diet-Fed Mice by Enhancing Insulin Signaling Independently of FGF21 Pathway (Presented as poster presentation, 1661-P)

Obanda D, Cefalu WT. Attenuation of Insulin Signaling by Protein Tyrosine Phosphatase 1B (PTP1B) Phosphorylation may be Modulated by AKT 1 and 2 Phosphorylation Levels (Presented at the 72<sup>nd</sup> Scientific Sessions of the American Diabetes Association, Poster Presentation, 1586-P)

Stenlof K, Cefalu WT, Alba M, Usiskin K, Zhao Y, Canovatchel. 81-OR - Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Improves Glycemic Control and Lowers Body Weight in Subjects with Type 2 Diabetes Inadequately Controlled With Diet and Exercise (Presented as Oral Presentation on Saturday, June 9, 2012, 81-OR)

Cefalu WT, Leiter LA, Debruin TW, Gause-Nilsson I, Sugg JE, Parikh SJ. Dapagliflozin Treatment for Type 2 Diabetes Mellitus Patients with Comorbid Cardiovascular Disease and Hypertension (Poster Presentation, 1056-P)

Cefalu WT, Leiter LA, Niskanen L, Xie J, Millington D, Canovatchel W, Meininger G. Efficacy and Safety of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Compared With Glimepiride in Patients with Type 2 Diabetes on Background Metformin (Presented as Late-Breaker Poster Presentation, 38-LB)

Leiter LA, Cefalu WT, Debruin TW, Gause-Nilsson I, Sugg JE, Parikh SJ. Efficacy and Safety of Dapagliflozin for Type 2 Diabetes Mellitus Patients with a History of Cardiovascular Disease (Poster presentation, 1114-P)

Luu LCT, Dubin R, Allerton T, Uwaifo GI, Cefalu WT. Ectopic Adipose Distribution In Normal Glucose Tolerant, Impaired Glucose Tolerant, and Type 2 Diabetic Vietnamese Americans (Poster presentation, 2039-P)

Luu LCT, Allerton T, Uwaifo GI, Dubin R, Cefalu WT. Vietnamese Americans Demonstrate Markedly Impaired Insulin Secretion Across Glycemic Status (Poster Presentation, 1750-P)

ABSTRACTS PRESENTED TO THE 70TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2011, SAN DIEGO, CA)

Wang ZQ, Yongmei U, Zhang XH, Ribnicky D, Cefalu WT. Effect of Ecdysterone on Hepatic AMP Activated Protein Kinase in Mice Fed with a High-Fat Diet (Poster Presentation, 1684-P)

Obanda DN, Ribnicky D, Wang ZQ, Cefalu WT. Mitigating Ceramide Induced Insulin Resistance in Rat Skeletal Muscle Culture Using Bioactives of Artemisia dracunculus L. (Poster Presentation, 1501-P)

Wang ZQ, Acharya T, Zhang X, Kirk-Ballard H, Yu Yongmei, Gilroy G, Ribnicky D, Cefalu WT, Floyd E. Botanical Modulation of the Ubiquitin Proteasome System in Skeletal Muscle (Poster Presentation, 1733-P)

ABSTRACTS PRESENTED TO THE 70TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2010)

Stull A, Wang ZQ, Zhang X, Yu Y, Qin J, Cefalu WT. Protein Tyrosine Phosphatase 1B (PTP1B) Abundance and Gene Expression in Skeletal Muscle Is Related to Clinical Parameters in Obese Subjects with Type 2 Diabetes. Diabetes 59 (Suppl 1) 2010 (Oral Presentation, Abstract 378)

Gabrielsen JS, Simcox JA, Huang J, Cefalu W, McClain D. Iron Negatively Regulates Serum Leptin Levels in Humans and Mice. Diabetes 59 (Suppl 1) 2010 (Poster Presentation, Abstract 1482-P).

Stull A, Lastor K, Johnson WD, Champagne CM, Cefalu WT. Dietary Supplementation with Blueberry Powder Enhances Insulin Sensitivity in Insulin Resistant Humans. Diabetes 59 (Suppl 1) 2010 (Poster Presentation, Abstract 1769-P)

ABSTRACTS PRESENTED TO THE 69TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2009)

Luu L, Newcomer B, Rood J, Qin J, Smith SR, Wang Z, Zhang X, Cefalu WT. Chromium Picolinate Supplementation Reduces Myocellular and Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus. Diabetes 58 (Suppl 1) 2009 (Oral Presentation, Abstract 174 OR)

Luu L, Crilly JF, Newcomer BR, Smith SR, Cefalu WT. Intermuscular Adipose Tissue in Soleus Muscle is Increased in Type 2 Diabetes. Diabetes 58 (Suppl 1) 2009 (Poster Presentation, Abstract 1748-P)

Stull AJ, Galgani JE, Johnson WE, Cefalu WT. African Americans, after controlling for other metabolic correlates, have greater metabolic flexibility than Caucasians Diabetes 58 (Suppl 1) 2009 (Presented as Poster Presentation, Abstract 1277-P)

ABSTRACTS PRESENTED TO THE 68TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2008)

Qin J, Wang Z, Zhang X, Cefalu WT. Clinical response to chromium picolinate supplementation in patients with type 2 diabetes depends on baseline metabolic parameters Diabetes 57 (Suppl 1) 2008 (Presented as Poster Presentation, 2874-P)

Coulter AA, Ribnicky D, Gupta S, Agyropoulis G, Wang ZQ, Raskin I, Cefalu WT. Effect of an alcoholic extract of *Artemisia dracunculus L.* on carbohydrate metabolism in humans Diabetes 57 (Suppl 1) 2008 (Presented as Poster Presentation, 2202-P)

Son LS, Qin J, Bordelon J, Yu Y, Ye X, Horswell R, Cefalu WT. Metformin increases Glut-4 translocation in obese diabetic human skeletal muscle independent of AMPK activity Diabetes 57 (Suppl 1) 2008 (Presented as Poster Presentation, 2196-P)

ABSTRACTS PRESENTED TO THE 67TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2007)

Cefalu WT, Rosenstock J, Schwartz P, Klioze S, Krasner A, Reis J, Reis R. Pulmonary Safety following Discontinuation and Readministration of Inhaled Human Insulin (Exubera) in Adults with Type 2 Diabetes. Diabetes 56 (Suppl1). 2007

Wang ZQ, Zhang X, Ye X, Cefalu WT. Chromium Picolinate Supplementation Enhances PI-3 Kinase Activity and Decreases PTP1B levels and Activity in Skeletal Muscle in Subjects with Type 2 Diabetes. Diabetes 56 (Suppl 1), 1765-P, 2007.

Wang ZQ, Ribnicky DM, Zuberi A, Zhang X, Yu Y, Ye X, Qin J, Son L, Raskin I, Cefalu WT. An extract of *Artemisia dracunculoides* L. increases insulin sensitivity and enhances insulin cellular insulin signaling in KKA<sup>y</sup> Mice. *Diabetes* 56 (Suppl 1), 610-P, 2007.

Coulter AA, Agyropoulos G, Ribnicky DM, Zhang X, Wang Z, and Cefalu WT. Reduction in PTP-1B Protein Levels in Skeletal Muscle by an alcoholic extract of *Artemisia dracunculoides* L. is phenotype dependent. *Diabetes* 56 (Suppl1), 1280-P, 2007

ABSTRACTS PRESENTED TO THE 66TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2006)

Wang ZQ, Ribnicky DM, Logendra S, Poulev A, Ma J, Yang H, Kennelly EJ, Raskin I, Liu X, Cefalu WT. Bioactives from an extract of *Artemisia dracunculoides* L. exhibit potent inhibitory effects on PTP 1B activity in human skeletal muscle culture from subjects with type 2 diabetes. *Diabetes* 55 (Suppl 1):613P, 2006.

Wang ZQ, Zhang XH, Cefalu WT, Dhurandhar NV. Effect of adenovirus-36 infection on aquaporins in preadipocytes and adipocytes. *Diabetes* 55(Suppl 1):1366P, 2006.

Hannaman SM, Wang ZQ, Zhang XH, Cefalu WT. Effect of magnesium depletion and replacement on glycogen content and insulin signaling in L6 muscle cell culture: Evidence for modulation on PTP 1B activity. *Diabetes* 55 (Suppl 1):2426, 2006. Published Only

Liu X, Qin J, Wang ZQ, Zhang XH, Wagner J, Cefalu WT. Effects of chronic caloric restriction on gene expression profile in skeletal muscle of cynomolgus monkeys (*Macaca fascicularis*). *Diabetes* 55(Suppl 1):1662P, 2006.

Jetton T, Wang ZQ, Matin J, Zhang XH, Cefalu WT. Chromium picolinate supplementation enhances GLUT-4 translocation in skeletal muscle in subjects with type 2 diabetes. *Diabetes* 55(Suppl 1):331-OR, 2006.

Floyd ZE, Wang ZQ, Kilroy GE, Cefalu WT, Gimble JM. Regulation of PPAR  $\alpha$  activity and proteasome-dependent degradation by resveratrol. *Diabetes* 55(Suppl 1):1911P, 2006.

Lefevre M, Wang ZQ, Ribnicky D, Raskin I, Zhang XH, Hulver M, Civitaress A, Ye J, Cefalu. Use of hierarchical cluster analysis to prioritize secondary screening of bioactive botanicals for treatment of insulin resistance. *Diabetes* 55(Suppl 1):2084, 2006. Published only

Morrison C. D, White C, Wang ZQ, Cefalu WT, Lee SY, Lawrence DS, Zhang ZY, Gettys G. Increased hypothalamic PTP 1B contributes to leptin resistance with age. *Diabetes* 55(Suppl 1):1739P, 2006.

ABSTRACTS PRESENTED TO THE 2006 EXPERIMENTAL BIOLOGY MEETING (SAN FRANCISCO, CA)

Wang ZQ, Liu X, Zhang XH, Cefalu WT. ACE inhibitors enhance insulin signaling by reducing PTP 1B protein abundance and its activity in primary skeletal muscle cells from type 2 diabetes. Presented as Poster Presentation

ABSTRACTS PRESENTED TO THE 3<sup>RD</sup> INTERNATIONAL CONFERENCE ON UBIQUITIN, UBIQUITIN-LIKE PROTEINS AND CANCER, FEB. 2006 (HOUSTON, TEXAS)

Wang ZQ, Zhang XH, Cefalu WT. Chromium piclinate inhibits ubiquitin-protease mediated degradation of IRSs in insulin treated 3T3-L1 adipocytes and human skeletal muscle cells. Oral presentation

ABSTRACTS PRESENTED TO THE 41<sup>ST</sup> ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES(SEPTEMBER 2005), ATHENS, GREECE

Wang ZQ, Cefalu WT, Hulver MW, Zhang XH. Effect of chromium picolinate on AMP-activated protein kinase alpha subunits and acetyl coenzyme A carboxylase in primary cultured human skeletal muscle cells. Oral presentation

ABSTRACTS PRESENTED TO THE 65TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2005)

Cefalu W, Serdarevic-Pehar M, for the Exubera Phase 3 Study Group: Long-Term Use of Exubera in Type 2 diabetes: Observations on Glycemic Control, Pulmonary Function and Antibody Formation. Diabetes, 54m Supplement 1, 356A (Oral Presentation).

Martin J, Matthews DE, Wang ZQ, Zhang X, Volaufova J, Cefalu WT: Effect of Chromium Picolinate on Body Composition, Insulin Sensitivity and Glycemic Control in Subjects with Type 2 Diabetes. Diabetes, 54 Supplement 1, 1778-P

Wang ZQ, Zhang X, Wagner J, Cefalu WT: Chronic Caloric Restriction enhances the AMP-Activated Protein Kinase Cascade in Skeletal Muscle of Cynomolgus Monkeys. Diabetes, 54 Supplement 1, 1781-P

ABSTRACTS PRESENTED TO THE 64TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2004)

Wang ZQ, Zhang XM, Ribnicky DM, Cefalu WT: Effect of an Alcoholic Extract of *Artemisia dracuncululus* (Tarralin<sup>TM</sup>) on Glucose Uptake in Human Skeletal Muscle Culture. Diabetes, 53: Suppl 2, 1706A, 2004.

ABSTRACTS PRESENTED TO THE 18TH INTERNATIONAL DIABETES FEDERATION CONGRESS (AUGUST 2003)

Cefalu WT, Martin JM, Wachtel D, Zhang XH, Wang ZQ. Chromium Picolinate Supplementation Increases Insulin-Stimulated Akt Phosphorylation *in vivo* in Skeletal Muscle from Subjects with Type 2 Diabetes. Diabetologia 2003: 46: Suppl 2, 154.

Wang ZQ, Zhang XH, Ramos-Nino ME, Cefalu WT. Gene Expression Analysis of the Effect of Chromium Picolinate in Human Skeletal Muscle Culture. Diabetologia 2003: 46: Suppl 2, 762A

ABSTRACTS PRESENTED TO THE 63RD ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2003)

Wang ZQ, Zhang XH, Ramos-Nino ME, Cefalu WT. Gene expression analysis of human skeletal muscle: Novel Genes potentially involved in chromium-enhanced insulin action.

ABSTRACT PRESENTED TO 38TH ANNUAL MEETING, EUROPEAN ASSOC FOR THE STUDY OF DIABETES, JERUSALEM, ISRAEL (SEPT 2002)

Cefalu, WT, Schneider, DJ, Carlson, HE, Migdal, P, et al. Effect of Combination Glipizide GITS/ Metformin on Fibrinolytic and Metabolic Parameters in Poorly Controlled Type 2 Diabetic Subjects.

Cefalu WT for the Exubera Phase III Study Group: Mealtime Rapid-acting Inhaled Insulin (Exubera) improves Glycaemic Control in Patients with Type 2 Diabetes Failing Combination Oral Agents: A 3 month, Randomized, Comparative Trial.

ABSTRACTS PRESENTED TO 62ND ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2002)

Cefalu WT, Beatty DJ, Fisher JC, Edelman SV. Long-term Continuous Glucose Monitor in Subcutaneous Tissue: Accuracy Results from a 25-Subject Study. Diabetes 2002; 51(Suppl 2): A48-OR.

Edelman SV, Bouvet M, Fisher JC, Cefalu WT: Glucose Sensor in the Subcutaneous Tissue: Continuous Data in Patients with Type 1 Diabetes. Diabetes 2002; 51(Suppl 2): A49-OR.

Wagenknecht LE, D'Agostino Jr, R, Rewers M, Karter A, Cefalu WT: Glycated Low-Density Lipoprotein is Independently Associated with Carotid Was Thickness in Persons with Type 2 Diabetes. Diabetes 2002; 51(Suppl 2): A978-P.

Wang ZQ, Zhang XH, Cefalu WT. Chromium Picolinate Increases Phosphoinositide 3-Kinase Activity, Glucose Uptake, and Glycogen Content in Cultured Human Skeletal Muscle Cells. Diabetes 2002; 51(Suppl 2): A575 (#2380-PO)

Bindra SS, Wang ZQ, Zhang XH, Cefalu WT. Effects of Oral Hypoglycemic Agents on Glucose Uptake in Human Skeletal Muscle Cell Culture. Diabetes 2002; 51(Suppl 2): A565 (#2337-PO).

Wang ZQ, Zhang XH, Komorowski JR, Juturu V, Cefalu WT. Enhancement of Glucose Uptake in Human Skeletal Muscle Culture: Conjugated Lijnoleic Acid, CLA Isomer t10 cis12, and Chromium Picolinate. Diabetes 2002; 51(Suppl 2): A567 (#2342-PO).

Dubin RL, Bindra SS, Wang ZQ, Zhang XH, Cefalu WT. Angiotensin-Converting Enzyme Inhibitors Increase Basal Glucose Uptake in Human Skeletal Muscle. Diabetes 2002; 51(Suppl 2): A566 (#2340-PO).

ABSTRACTS PRESENTED TO 61ST ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2001)

Cefalu WT, Schneider DJ, Sobel BE. Equieffective Diminution of Elevated Plasminogen Activator Type-1 in Blood with Glipizide GITS or Metformin in Markedly Obese, Poorly Controlled, Type 2 Diabetic Subjects. Diabetes 2001; 50(Suppl 2):A149.



Calcagni CB, Jetton TL, Monte AA, Wang ZQ, Cefalu WT. Chromium Picolinate Improves Insulin Sensitivity and Normalizes Glut-4 Translocation Patterns Following Insulin Stimulation in the Insulin Resistant, JCR:LA-Corpulent Rat. *Diabetes* 2001; 50(Suppl 2):A275.

Wang ZQ, Zhang XH, Wagner JD, Cefalu WT. Long-Term Caloric Restriction Enhances Phosphatidylinositol-3 Kinase Activity in Skeletal Muscle of Cynomolgus Monkeys. *Diabetes* 2001; 50(Suppl 2):A294

ABSTRACT PRESENTED TO 97TH ANNUAL AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE (MAY 2001)

Cefalu WT, Teeter JG, Balagtas CC, Gelfand RA, Landschulz WH. Sustained Long-Term Efficacy and Pulmonary Safety of Inhaled Dry-Powder Insulin.

ABSTRACTS PRESENTED TO 17<sup>TH</sup> INTERNATIONAL DIABETES FEDERATION (NOVEMBER 2000)

Wang ZQ, Zhang X, Baldor LC, Russell JC, Cefalu WT. Chromium Picolinate Improves Carbohydrate and Lipid Metabolism and Enhances Skeletal Muscle Glut-4 Translocation in Obese, Hyperinsulinemic Rats.

Cefalu WT, Balagtas CC, Landschulz WH, Gelfand RA. Sustained Efficacy and Pulmonary Safety of Inhaled Insulin During 2 Years of Outpatient Therapy.

Wang ZQ, Zhang X, Cefalu WT. Chromium Picolinate and Biotin Enhance Glycogen Synthesis and Glycogen Synthase Gene Expression in Human Skeletal Muscle Culture.

ABSTRACTS PRESENTED TO 60TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 2000)

Wang ZQ, Zhang XH, Baldor LC, Russell JC, Cefalu WT. Chromium Picolinate Enhances Insulin Sensitivity in an Animal Model for the Metabolic Syndrome: The Obese, Insulin Resistant JCR:LA-Corpulent Rat.

Cefalu WT, Balagtas CC, Landschulz WH, Gelfand RA. Sustained Efficacy and Pulmonary Safety of Inhaled Insulin During 2 Years of Outpatient Therapy.

Abstracts presented to 36<sup>th</sup> Annual Meeting, European Assoc for the Study of Diabetes (Sept 2002)

Cefalu WT, Balagtas CC, Landschulz WH, Gelfand RA. Sustained Efficacy and Pulmonary Safety of Inhaled Insulin During 2 Years of Outpatient Therapy.

ABSTRACTS PRESENTED TO 59TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 1999)

Cefalu WT, Bell-Farrow AD, Terry JG, Wang ZQ, King T. Abdominal Fat Distribution with Combination Glipizide GITS/Metformin Treatment in Type 2 Diabetics.

Wang ZQ, Cefalu WT, Bell-Farrow AD. Caloric Restriction Increases Insulin Stimulated Glucose Transporter 4 Content of Muscle Membrane in Cynomolgus Monkeys.

Wang ZQ, Zhang X, Cefalu WT. Effect of Chromium Picolinate and Biotin on Glucose Uptake in Human Skeletal Muscle Culture.

ABSTRACTS PRESENTED TO 57TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 1997)

Redmon EM, Bell-Farrow AD, Wang ZQ, McBride DG, Cefalu WT. Clinical Validation of a New Rapid Fingerstick Test for Glycated Proteins (Fructosamine).

Edwards IJ, Terry JG, Bell-Farrow AD, Cefalu WT. Combination Glipizide GITS/Metformin Treatment Reduces Low Density Lipoprotein Binding to Arterial Proteoglycans in NIDDM.

Edwards IJ, Wagner JD, Litwak KN, Cefalu WT, Rudel LL. Diabetes-Induced Modification of Plasma Low Density Lipoproteins Leads to Increased Interaction with Arterial Proteoglycans.

Cefalu WT, Bell-Farrow AD, Wang ZQ, McBride DG, Stegner J, Terry JG, Morgan TM. The Effect of Chromium Supplementation on Carbohydrate Metabolism and Body Fat Distribution.

ABSTRACTS PRESENTED TO 10TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY (1996)

Cefalu WT, Bell-Farrow AD, Wang ZQ, McBride D, Stegner J, Dalgleish DC, Tive L, Fischette CT. Glipizide GITS Increases and Maintains Insulin Sensitivity *In vivo* in NIDDM.

ABSTRACTS PRESENTED TO AMERICAN FEDERATION FOR AGING RESEARCH SCIENTIFIC MEETINGS (MAY 1996)

Cefalu WT, Bell-Farrow AD, Wagner JD, Wang ZQ. Improved Insulin Sensitivity in Chronic Caloric Restriction State is Associated with Reduced Insulin Binding and No Net Change in Glut-4 or Glut-1 Level.

Cefalu WT, et al. Caloric Restriction Improves Insulin Sensitivity and Reduces Intra-abdominal Fat in Cynomolgus Monkeys. Abstract presented to 56th Annual Meeting and Scientific Sessions, ADA (June 1996).

Cefalu WT, Bell-Farrow AD, McBride D, Wang ZQ, Tive L, Fischette CT, Terry JG. Combination Glipizide GITS/Metformin Normalizes Glucose and Improves Insulin Sensitivity in Hyperinsulinemic Moderately Well Controlled NIDDM.

ABSTRACTS PRESENTED AT 55TH ANNUAL MEETING AND SCIENTIFIC SESSIONS, ADA (JUNE 1995)

Cefalu WT, Bell-Farrow AD, Wang ZQ, et al. Insulin Sensitivity *in vivo* is Improved after Glipizide GITS Treatment.

Werbel SS, Crouse JR, Cefalu WT, et al. Hormone Replacement Therapy Reduces Intra-Abdominal Fat Accumulation in Post-Menopausal Women.

Werbel SS, Bell-Farrow AD, Cefalu WT, Wang ZQ. Effect of Hormone Replacement Therapy on Insulin Sensitivity in Post-Menopausal Women.

ABSTRACT PRESENTED TO 47TH ANNUAL MEETING, GERONTOLOGICAL SOCIETY OF AMERICA (NOVEMBER 1994)

Cefalu WT, Sonntag W, Baynes JW, et al. Caloric Restriction (CR) Decreases the Rate of Age-Dependent Accumulation of the Glycoxidation Products N<sup>E</sup>(Carboxymethyl)lysine (CML) and Pentosidine (P) in Rat Skin.

ABSTRACTS PRESENTED AT 1994 NATIONAL MEETING OF THE AMERICAN DIABETES ASSOCIATION

Cefalu WT, Kourides I, Fischette C. Glipizide GITS vs. Immediate-Release Glipizide in the Management of Patients with NIDDM: Evidence for Increased Insulin Sensitivity after Glipizide GITS Treatment.

Werbel SS, Faulk KL, Cefalu WT, Wang ZQ, Bell-Farrow AD. Intra-abdominal Fat by MRI Scanning: Relationship to Insulin Resistance and Age According to Gender.

ABSTRACT PRESENTED AT 46TH ANNUAL MEETING, GERONTOLOGICAL SOCIETY OF AMERICA (NOVEMBER 1993)

Cefalu WT, Faulk K, Bell-Farrow AD, Wang ZQ, Terry JG, Crouse JR, Werbel SS. Insulin Resistance of Aging: Relationship to Intra-Abdominal Fat by Magnetic Resonance Imaging.

ABSTRACTS PRESENTED AT 1993 NATIONAL MEETING OF THE ADA (JUNE 1993)

Cefalu WT, Wagner JD, Bell-Farrow AD, Wang, ZQ, Toffolo G, Adams M: The Effects of Hormone Replacement Therapy on Insulin Sensitivity in Postmenopausal Cynomolgus Monkeys. Diabetes 1993, 42:Suppl 1, 534A.

Wagner JD, Carlson CS, Johnson KH, Cefalu WT, O'Brien TD: A New Animal Model of NIDDM: Spontaneous Diabetes Mellitus in Cynomolgus Monkeys. Diabetes 1993, 42:Suppl 1, 741A.

ABSTRACT PRESENTED AT 45TH ANNUAL MEETING, GERONTOLOGICAL SOCIETY OF AMERICA (NOVEMBER 1992)

Cefalu, WT, Wagner JD, Boles TH: N<sup>□</sup>-(Carboxymethyl) Lysine Levels in Arterial Collagen in Non-Diabetic Non-Human Primates: Correlation with Age, but not with Extent of Atherosclerosis. The Gerontologist, Vol 32, 1992.

ABSTRACT PRESENTED TO 1992 NATIONAL MEETING - AFCR

Cefalu WT, Wagner JD, Anthony MS. Hyperinsulinemia and Central Obesity in a Non-human Primate (*Macaca fascicularis*) Model for Cardiovascular Risk Factors. Clinical Research 1992, 40:2,230A.

ABSTRACT PRESENTED TO 1992 ADA CONFERENCE (JUNE 1992)

Werbel SS, Crouse JR, Petty ML, Wang ZQ, Cefalu WT: Glucagon and Glipizide Stimulated Insulin/C-Peptide: Correlation to Intra-abdominal Fat Mass as Determined by Magnetic Resonance Imaging. Diabetes 41:Suppl 1, 241.

ABSTRACTS PRESENTED AT AGS/AFAR SCIENTIFIC SESSION (MAY 1991)

Cefalu WT, Ettinger WH, Bell-Farrow AD, Thomas J: Serum Fructosamine as a Screening Test for Diabetes Mellitus in the Elderly. (Abstract P-167).

Cefalu WT, Bell-Farrow AD, Wang ZQ, Sonntag WE: Effect of Caloric Restriction in Aging Rats on Glycation of Blood-Brain Barrier and Brain Membrane Proteins. (Plenary Session, Abstract A-4).

ABSTRACTS PRESENTED AT THE INTERNATIONAL DIABETES FEDERATION CONGRESS (JUNE 1991)

Wagner JD, Welles EG, Bell-Farrow AB, Anthony AS, Cefalu WT: Non-Ketotic Hyperglycemia and Obesity Proceeding Insulinopenic State in Aged Monkeys. *Diabetes* 40:Suppl 1, 873A, 1991.

Bell-Farrow AD, Patty ML, Izlar CB, Cefalu WT: Clinical Evaluation of a New, Second Generation Fructosamine Assay. *Diabetes* 40:Suppl 1, 1915A, 1991.

Petty ML, Bell-Farrow AD, Izlar CB, Kiger FD, Cefalu WT: Glycated Hemoglobin by Automated Affinity High-Performance Liquid Chromatography. *Diabetes* 40:Suppl 1, 1603A, 1991.

Cefalu WT, Bell-Farrow AD, Wang ZQ: *In Vivo* Bioavailability of Albumin-Bound Sulfonyleureas: Effect of Chronic Clinical Hyperglycemia. *Diabetes* 40:Suppl 1, 1341A, 1991.

Wang ZQ, Bell-Farrow AD, Ralapati S, Cefalu WT: Aminoguanidine and Acetyl-Salicylic Acid Inhibit Non-Enzymatic Glycosylation of Peripheral Tissue Membranes *In Vivo*. *Diabetes* 40:Suppl 1, 495A, 1991.

*Additional Abstract presentations*

Cefalu WT, Bell-Farrow A, Wang Z, Ralapati S. Detection of furosine in biomedical samples using a novel and rapid high performance liquid chromatography system. Presented at the XVth International Carbohydrate Symposium, Yokohama, Japan, August 1990.

Wang ZQ, Bell-Farrow AD, Ralapati S, Cefalu WT. Liver and kidney tissue membranes as tissue markers for non-enzymatic glycation. *Diabetes* 1991;40(7):90-907.

Wilensky MK, Downes TR, Bell-Farrow AB, Cefalu WT. Serum glycated protein level as a marker for stress hyperglycemia in acute myocardial infarction. *Clin Res* 1990, 524A.

Devo D, Navid F, Cefalu WT. Serum protein glycation in type 1 diabetic patients does not effect routine hematologic profile. *Clin Res* 1989;38:118A.

Wong J, Madiedo M, Cefalu WT. Diabetic camp participation alters lipid and glycemic profile in type 1 diabetic children. *Clin Res* 1989;38:88A.

Cefalu WT, Prather K, Murphy W. Clinical evaluation of glycated protein assays in the elderly. *Clin Res* 1989;38:88A

Rinker R, Cefalu WT. Assessment of clinical quantifiable vibratory testing in screening for neuropathy in type 1 diabetic children. *Clin Res* 1989;38:116A.

Krems S, Livaudais J, Shah S, Cefalu WT. Protein/creatinine ratios may not predict total proteinuria in type 1 diabetic patients with normal renal function. *Clin Res* 1989;38:116A.

Cefalu WT, Chester D, Prather K. Studies on the role of serum glycated protein (fructosamine) to detect and monitor the gestational diabetic. *Diabetes* 1989;38:127A.

Yagci A, Alptekin N, Cefalu WT, Karcioğlu. Lipid peroxide levels of serum, lens and retina in diabetic rats. *Invest Ophthal Visual Science* 1989;30:30A.

Cefalu W, Brownlee M, Prather K. Aminoguanidine prevents hyperglycemia-induced inhibition of albumin-mediated blood-brain barrier transport of estradiol in vivo. *Clin Res* 1988;36:150A.

Cefalu WT, Mejia E, Puente R. Correlation of serum fructosamine activity with mean blood glucose in type 1 diabetic children. *Clin Res* 1988;36:22A.

Mejia E, Shah S, Puente G, Cefalu W. Predictive value of first morning protein concentrations in assessing abnormal protein excretion in type 1 diabetic children. *Clin Res* 1988;36:156A.

Puente R, Mejia E, Shah S, Cefalu W. Assessment of protein excretion rate in type 1 diabetic children attending diabetes camp with use of overnight timed urine collection. *Clin Res* 1988;36:158A.

Cefalu W, Murray F, Prather K. Serum from diabetic impotent males inhibits testosterone transport into rat brain in vivo. *Clin Res* 1988;36:150A.

Puente GR, Fleischacker D, Macaulay K, Cefalu WT. Evaluation of serum glycosylated protein level (fructosamine) in type 1 diabetic children attending diabetes camp. *Diabetes* 1988;37:134A.

Cefalu W, Brownlee M, Prather K. Advanced glycosylation of human serum albumin inhibits estradiol transport across the rat blood-brain barrier in vivo. *Endocr Soc Annu Meet Prog Abstr* 1988;733.

Cefalu WT, Prather K. Glycosylation of human serum albumin in serum from diabetic impotent males inhibits testosterone transport into rat brain and liver in vivo. *Diabetes* 1988;37:118A.

Cefalu W, Chester D, Biswas M, Pernal M. Screening for gestational diabetes: evaluation of serum glycosylated protein assays. *South Med J* 1988;81 (suppl 4):42.

Cefalu WT, Pardridge WM. Enhanced lymph node transport and augmented metabolism of testosterone in the WR-6 lymphocytic leukemia in the rat. *Clin Res* 1987;35:10A.

Cooper J, Cefalu W, Parker T, Johnson C. Validity of the fructosamine assay as short-term index of glycemic control. *Diabetes* 1987;36:119A.

Cefalu WT. Glycosylation of human serum albumin inhibits brain and liver transport of estradiol in vivo. *Diabetes* 1987;36:101A.

Cefalu WT, Pardridge WM. Estradiol, but not testosterone, is available for transport into salivary gland and lymph node from the circulating human sex hormone binding globulin (SHBG) pool in the rat. *Clin Res* 1986;34:21A.

Cefalu WT, Pardridge WM. Testosterone concentrations in saliva are low because of active glandular metabolism. *Endocr Soc Annu Meet Prog Abstr* 1986;705A.

Cefalu WT, Pardridge WM. Augmented transport and metabolism of testosterone in lymphoid neoplasia in the rat. *Clin Res* 1986;34:422A.

Cefalu WT, Pardridge WM. Transport of sex hormone binding globulin (SHBG)-bound estradiol, but not testosterone, into salivary gland and lymph node in the rat. *Clin Res* 1986;34:542A.

Cefalu WT, Pardridge WM. Salivary testosterone levels are a reflection of active glandular metabolism. Clin Res 1986;34:21A.

Cefalu WT, Pardridge WM, Premachandra BN. Testosterone and estradiol bound to albumin in familial dysalbuminemic hyperthyroxinemia (FDH) are freely available for transport into liver and brain. Clin Res 1985;33:25A.

Pardridge WM, Cefalu WT. Restricted transport of a highly lipid soluble peptide (cyclosporin) through the blood-brain barrier. Endocr Soc Annu Meet Prog Abstr 1985;890.

Chaudhuri G, Steingold K, Cefalu WT, Pardridge WM, Judd H. Enhanced hepatic availability of estrogen preparations used for replacement therapy. Soc for Gynecol Invest, March 1985.

Pardridge WM, Cefalu W, Premachandra BN. Thyroxine (T4) bound to albumin in familial dysalbuminemic hyperthyroxinemia (FDH) is not available for transport into rat liver. Clin Res 1985;33:29A.

Cefalu WT, Pardridge WM. Restrictive transport of albumin-bound testosterone into rat salivary gland. Endocr Soc Annu Meet Prog Abstr 1985;1056.

Cefalu WT, Pardridge Wm. Restricted transport of a highly lipid soluble peptide (cyclosporin) through the blood-brain barrier. Clin Res 1985;33:25A.

Cefalu W, Yang J, Pardridge WM. Major blood-brain barrier phospho-proteins. Soc Neurosci Abstr 1984;10:1162.

## **LECTURES, SPEECHES, EXHIBITS, FILMS:**

### **Presentations:**

#### A. International Invited Lectures/Presentations

“Use of Non-Enzymatic Glycated Protein Assays in the Diabetic Population,” University of Geneva, Geneva, Switzerland, September 1989.

“Detection of Amadori Products in Biomedical Samples Using a Rapid and Novel High-Performance Liquid Chromatographic System,” XVth International Carbohydrate Symposium, Yokohama, Japan, August 1990.

“Non-Enzymatic Glycation: An Etiology for Complications, A Marker for Glycemic Control,” Department of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan, August 1990.

“Effect of Combination Glipizide GITS/Metformin on Insulin Sensitivity in Hyperinsulinemic, NIDDM Subjects,” European Association for the Study of Diabetes Symposium, Vienna, Austria, August 1996.

“Role of Insulin Resistance and Its Treatment in NIDDM,” presented as guest lecturer to Turkish endocrinologists, Istanbul, Turkey, March 1997.

Visiting Professor and Lecturer: "Current and Evolving Therapies for NIDDM," Shanghai, Guanzhou, Beijing, China, May 1997.

"New Approaches to the Treatment of Type 2 Diabetes," presented as guest lecturer for Indonesian Endocrinologists, Singapore, September 1997.

"Advances in the Management of Type 2 Diabetes," Presented at the 1<sup>st</sup> Russian Congress of Diabetes, Moscow, June 1998.

"Chromium and Insulin Sensitivity," Presented at Trace Elements in Man and Animals (TEMA) 10, Evian, France, May 1999.

"Alternative Routes of Insulin Administration," Artificial Insulin Delivery Systems, Pancreas and Islet Transplantation (AIDSPIT) Study Group of the European Association for the Study of Diabetes 19<sup>th</sup> Annual Meeting in Igls, Austria, January 2000.

"Update on Management of Type 2 Diabetes: A Worldwide Epidemic," Invited Professor and Consultant, Beijing, Shanghai, and Guanzhou, China; June 23-30, 2000.

"Management of Type 2 Diabetes: A Y2K Approach." Presented as a satellite symposium at the European Association for the Study of Diabetes Annual Meeting in Jerusalem; September 15, 2000.

"Novel Routes of Insulin Delivery for Patients with Type 1 and Type 2 Diabetes." Presented as a satellite symposium on "Achieving Treatment Goals in the Management of Diabetes" at the European Association for the Study of Diabetes Annual Meeting in Jerusalem; September 17, 2000.

"Pulmonary Delivery of Insulin as an Effective Treatment for Type 1 and Type 2 Diabetes," Presented at the European Association for the Study of Diabetes Annual Meeting, Jerusalem, September 20, 2000.

"Future Perspectives on the Management of Diabetes." Presented at a symposium entitled "Metabolic and Vascular Benefits of Treating Insulin Resistance," 11<sup>th</sup> Congress of the Latin American Association of Diabetes, and the 3<sup>rd</sup> Uruguayan Congress of Diabetes, November 13, 2001, Puente del Este, Uruguay.

"Modulation by PPARs in Controlling Diabetic Cardiovascular Disease." Presented at the First National Symposium for the Prevention of Cardiovascular Disease, Foundation of Cardiovascular Disease Prevention, April 2002, Caracas, Venezuela.

"Molecular Aspects of Insulin Resistance." Presented at an "Insulin Resistance" symposium at the 1<sup>st</sup> National Session for Obesity, Venezuelan Association for the Study of Obesity, June 7, 2002, Caracas, Venezuela.

"Rational Use of Insulin Sensitizers", Presented at an "Insulin Resistance" symposium at the 1<sup>st</sup> National Session for Obesity, Venezuelan Association for the Study of Obesity, June 7, 2002, Caracas, Venezuela.

“Chromium Picolinate supplementation increases insulin-stimulated Akt phosphorylation *in vivo* in skeletal muscle from subjects with type 2 diabetes”, presented at the 18<sup>th</sup> International Diabetes Federation Congress, Paris France, August 24-29<sup>th</sup>, 2003

“Alternative Insulin Delivery Systems”, Presented (August 24<sup>th</sup>) at a Satellite Symposium of the 18<sup>th</sup> International Diabetes Federation Congress, Paris, France, August 24-29, 2004. The main symposium was entitled “The Road Less Traveled: Diabetes Treatment Beyond Glucose”

“Non-Traditional Cardiovascular Markers”, presented as a Satellite Workshop entitled “Growth Hormone and Insulin like Growth Factors: Growth and Beyond”, May 16-17, 2004 as part of the 36<sup>th</sup> International Symposium: GH and Growth Factors in Endocrinology and Metabolism, May 14-15, 2004, Geneva, Switzerland.

“Chromium and Metabolic Syndrome”, presented on November 7<sup>th</sup> at a symposium entitled “Metabolic Syndrome and Trace Elements” held during the VII Conference of the International Society for Trace Element Research in Humans (ISTERH), November 7-12, 2004, Bangkok, Thailand

“Insulin Therapy for Type 2 Diabetes Mellitus: Emerging Paradigms for Treatment”, presented at a plenary session on December 1, 2005 at the XLV International Congress of Nutrition and Endocrinology, Merida, Yucatan, Mexico (November 28 – December 3, 2005)

“Sustained Efficacy and Tolerability of Inhaled Human Insulin (Exubera). Therapy over 2 years: Patients with Type 2 Diabetes”. Presented as poster on September 12, 2006 at the 42<sup>nd</sup> Annual Meeting of the European Association for the Study of Diabetes in Copenhagen, Denmark, September 14-17, 2006.

“Clinical Research with Inhaled Insulin”, presented at a plenary symposium entitled “Update on Recent Advances from Clinical Research” at the XLVI International Congress of Nutrition and Endocrinology, Veracruz, Mexico. Presented on October 26, 2006.

“Metabolic Effects of Inhaled Insulin”, Presented to the Puerto Rican Society for Endocrinology and Diabetology, November 2, 2006, Ritz-Carlton Hotel, San Juan, Puerto Rico

“Diabetes Tomorrow: Innovative Solutions to the Wider Use of Insulin Therapy”. Presented in a symposium entitled “Insulin for People with Diabetes: Meeting the Unmet Need” at the International Diabetes Federation meeting, Cape Town, Africa. Presented on December 3<sup>rd</sup>, 2006.

“Incretins: The Promise of New Hormone Therapy”, presented as part of Symposium III entitled “Prevention and Treatment of Obesity and Metabolic Syndrome: Obesity” at The 4<sup>th</sup> Asia-Oceania Conference on Obesity, Feb 9-11, 2007, Seoul, Korea. Presented on Feb 11<sup>th</sup>.



“Inhaled Insulin: A Turning Point in the History of a Proven Therapy”, presented in a symposium entitled “Inhaled Insulin- Beyond the Borders of Traditional Insulin Therapies-Experiences-Prospects-Recommendations” as part of The 10<sup>th</sup> Panhellenic Congress on Diabetes, International Conference Center of the Athens Concert Hall, Athens, Greece, Feb. 28-March 4, 2007. Presented on March 2, 2007

“Clinical Use and Review of Cases Studies with DPP-IV Inhibitors”. Presented at a Merck Sponsored Symposium entitled “Confronting the Epidemic of Type 2 Diabetes: Can Novel Therapies Addressing Islet Dysfunction Help Patients Get to Goal?”. Held at Ludwig Erhard Haus, Berlin, Germany, May 12, 2007

“Beyond Oral Therapy: Which Insulin to Start With? Inhaled Insulin Therapy”, presented in a symposium entitled “Optimal Glycaemic Control Under Scrutiny: What, Why and How?” in conjunction with the 43<sup>rd</sup> Annual Meeting of the European Association for the Study of Diabetes (EASD). Presented on September 17, 2007, Rembrandt Hall, Amsterdam RAI Convention Centre, Amsterdam, The Netherlands.

“Incretins Based Therapy for Type 2 Diabetes”, presented at the 8<sup>th</sup> Pan Arab Congress on Endocrinology and Diabetes, Kuwait City, Kuwait. Presented on November 11, 2007

“Evolving Concepts in the Management of Type 2 Diabetes”, presented at the Shanghai Jiaotong University Conference on Current Focus of Diabetes 2007: Advances in Pathogenesis and Management. Presented on Nov 13, 2007

“Changing Paradigms: Need for Early Aggressive Management in Type 2 Diabetes Mellitus”. Presented to the Philippine College of Physicians (Central Luzon Chapter) , Philippine Academy of Family Physicians (Angeles City and Pampanga Chapter) and Pampagna Medical Society on Feb. 12, 2008 in Pampanga, Philippines and to the Philippine Academy of Family Physicians, Feb. 13, 2008 in Manila, Philippines

“The Management of Cardiovascular Disease in Diabetes: The Two Faces of PPARS”, presented as a Plenary Lecture of the Joint 13<sup>th</sup> Annual Convention of the Philippine Society of Hypertension and Philippine Lipid and Atherosclerosis Society (Resolving Controversies in Hypertension, Atherosclerosis and Dyslipidemia) Presented on Feb 14, 2008 in Manila, Philippines

“Current Status of Inhaled Insulin”, presented as a Plenary Lecture of the XIX Congress of the Spanish Association of Diabetes. Presented on Feb. 19, 2008 in Seville, Spain.

“Inhaled Insulin Overview”. Presented at the Take Control Peaks and Valleys™ (TCPV) European Conference, Lisbon, Portugal (February 28-March 1, 2008). SANA Lisboa Hotel Presented on March 1, 2008.

“CVD Risk in Type 2 Diabetes: An Eye Towards Non-Traditional Risk Factors”. Presented at the Take Control Peaks and Valleys™ (TCPV) Asia Conference, Hong Kong (May 14-17, 2008). Kowloon Shangri-La Hotel. Presented on May 17, 2008.

“Restoring Glucose Homeostasis with Incretin Therapy: New Perspectives on Old Challenges”. Seminar given to the Division of Endocrinology (12:30 pm Conference) and a seminar given at the Department of Cardiology (3:30pm Conference), National University Hospital, Singapore, August 21, 2008.

“Restoring Glucose Homeostasis with Incretin Therapy: New Perspectives on Old Challenges”. Lecture given at the National Heart Centre, Singapore, August 22, 2008

“Diabetes and Cardiovascular Disease – Impact of Optimizing Glycemic Management”. Presented at a CME Symposium as part of the Launch of the National DOT (Delivering on Target) Program of the Singapore Health Services and National Healthcare Group. Swissotel Merchant Court Hotel. Presented on August 23, 2008 in Singapore.

“Overview of Clinical Profile of Sitagliptin Combination Therapy”. Presented at the MSD EMAEAC (Europe Middle East Africa Canada) Speaker Forum, Budapest, Hungary (September 26-27, 2008). Budapest Hilton Hotel. Presented on September 27, 2008

“Management Strategies for Pre-Diabetes”. Presented at the Take Control Peaks and Valleys™ (TCPV) Asia Conference, Singapore (February 18-21, 2009). Grand Mercure Roxy Hotel. Presented on February 20, 2009.

“Overview of Clinical Profile of Sitagliptin Combination Therapy: A Case Study Approach”. MSD Asia Pacific Speaker Forum, Hong Kong (February 27-28, 2009). Conrad Hotel. Presented on February 28, 2009

“Overview of Clinical Profile of Sitagliptin Combination Therapy: A Case Study Approach”. Presented at the MSD EMAEAC (Europe Middle East Africa Canada) Speaker Forum, Amsterdam, The Netherlands (March 6-7, 2009). Movenpick Hotel. Presented on March 7<sup>th</sup>, 2009

“Management Strategies for Pre-Diabetes”. Presented at the Take Control Peaks and Valleys™ (TCPV) Barcelona Conference, Barcelona, Spain (May 6-9, 2009). Hotel Fira Palace Barcelona. Presented on May 8, 2009.

“Incretins role in glucose homeostasis: therapeutic options in type 2 diabetes”. Lecture given to the Academy of Medical Science of Bilbao (AMSB), Bilbao, Spain. Lecture was given on May 12, 2009

“Diabetes and Cardiovascular Disease – Impact of Recent Clinical Trial Data”. Presented at a Scientific Symposium (Symposium 12) of the of the 52<sup>nd</sup> Annual Meeting of the Japan Diabetes Society (May 21 – 24, 2009) in Osaka, Japan. The Symposium was entitled “‘Light and Shadow’ in Intensive Therapy for Diabetes. Presented at the Osaka International Convention Center on May 24<sup>th</sup>, 2009.

“A Discussion of Clinical Case Studies: Sitagliptin as Monotherapy or Combination Therapy”, presented at a MSD Scientific Symposium of the 45<sup>th</sup> Annual Meeting of the European Association for the Study of Diabetes (29<sup>th</sup> September – 2 October 2009) in Vienna, Austria. The Symposium was entitled “Controlling Obstacles to Glycemic Control in Type 2 Diabetes: The Role of Sitagliptin in Clinical Practice. Presented in Basch Hall, Messe Wien Congress

Center on September 29<sup>th</sup>, 2009

“The Next Step after Metformin for Glycemic Control in CVD Disease”. Presented at a Scientific Symposium of the SEC 2009-National Congress of the Spanish Society of Cardiology (October 22-24, 2009) in Barcelona, Spain. The Symposium was entitled “Treating Diabetic Patients with Heart Disease” Presented on October 22, 2009.

“Impact of Intensive Therapy on Microvascular and Macrovascular Complications”. Presented at a Scientific Symposium of the The XVII Congress of the Brazilian Diabetes Society, Fortaleza, Brazil (November 18 – 21, 2009). The Symposium was entitled “New Horizons in the approach to Treatment of Type 2 Diabetes”. Presented on November 21<sup>st</sup>, 2009

“Type 2 Diabetes and Glycemic Control: Analysis of the Clinical Therapeutic Options”. Presented as a plenary lecture of the The X Paraguayan Congress of Internal Medicine, Asunion, Paraguay (April 28 – May 1, 2010). The lecture was given on April 28, 2010

“Approach of the Global Cardio-Metabolic Risk: New aspects and Un-resolved Topics”: Presented as a plenary lecture of the The X Paraguayan Congress of Internal Medicine, Asunion, Paraguay (April 28 – May 1, 2010). The lecture was given on April 29, 2010

“Potential of Incretin Therapies in the Prevention of Type 2 Diabetes”. Presented at a Scientific Symposium of the The X Paraguayan Congress of Internal Medicine, Asunion, Paraguay (April 28 – May 1, 2010). The Symposium was entitled “Proactive Interventions beyond Lifestyle for Diabetes Prevention”. Presented on April 28, 2010

“Lessons to Learn from CV Outcome Studies”. Presented at the 3<sup>rd</sup> Latin American Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (March 13-16, 2014). Presented in Panama City, Panama on March 14, 2014.

“GLP-1 Therapies: What do clinicians need to know in 2015?”. Presented at the “Standing Together Against Diabetes meeting hosted by the American Diabetes Association in Bangkok, Thailand on March 14, 2015.

“How impeccable are the best papers in Diabetology”. Presented at the 2<sup>nd</sup> EASD Minkowski Clinical Research Course in Kaunas, Lithuania on September 3, 2015.

“The Clinical Research and Discovery Process: A Move toward Translation”. Presented at the 2<sup>nd</sup> EASD Minkowski Clinical Research Course in Kaunas, Lithuania on September 3, 2015.

“Essential to writing a successful paper in general and for *Diabetes Care*.” Presented at the 2<sup>nd</sup> EASD Minkowski Clinical Research Course in Kaunas, Lithuania on September 3, 2015.

“Initial use of combination therapy: No, Timing is not the issue!” Presented at the 5<sup>th</sup> World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Istanbul, Turkey on November 6, 2015.

“An overview of outcome studies: Evolutions in rationale, design and conduct.” Presented at the 5<sup>th</sup> World Congress on Controversies to Consensus in Diabetes, Obesity and

Hypertension in Istanbul, Turkey on November 7, 2015.

“Metabolic dysregulation and insulin action: human phenotypic considerations.” Presented at the Symposium on Molecular and Physiological Aspects of Diabetes Mellitus at the Karolinska Institute in Stockholm, Sweden on November 13, 2015.

“Prevention and Management of Diabetic Kidney Disease.” Presented at the “Standing Together Against Diabetes meeting hosted by the American Diabetes Association in Taipei, Taiwan on March 19, 2016.

“How close are we to revolutionizing diabetes management?.” Presented at the European Association for the Study of Diabetes annual meeting in Munich, Germany on September 12, 2016.

“Diabetes care – are we in a golden era?” Presented at the Chinese University of Hong Kong Distinguished Lecture Series on Diabetes in Hong Kong on November 7, 2016.

“How to publish in top diabetes journals?” Presented at the Chinese University of Hong Kong Distinguished Lecture Series on Diabetes in Hong Kong on November 7, 2016.

“What clinical strategies can we define as “revolutionizing” diabetes management” Presented at the Diabetes and Beyond: Diabetologists Congress in Tel Aviv, Israel on December 15, 2016.

“Insulin’s old and new role in diabetes management.” Presented at the Diabetes and Beyond: Diabetologists Congress in Tel Aviv, Israel on December 16, 2016.

“Dissecting the peer review process of a top cited paper.” Presented at the Diabetes and Beyond: Diabetologists Congress in Tel Aviv, Israel on December 16, 2016.

#### B. International: Invited Moderator/Chairman

Served as Chairman of the “Optimizing Control in Diabetes Coalition Roundtable” held at the Hempel Hotel, London, England, March 3-4, 2006. The Coalition reviewed the results of the Optimize study which evaluated patient perceptions toward diabetes treatment and was evaluated in 7 countries.

Moderated Session 3 entitled “Case Presentation with Panel Discussion” at the Take Control Peaks and Valleys™ (TCPV) Asia Conference, Shanghai, China (March 25-27, 2010). The Westin Bund Center. Session 3 was held on March 25, 2010

Moderated Session 5 entitled “Debate: Most Effective Treatment for Obese T2DM is Bariatric Surgery” at the Take Control Peaks and Valleys™ (TCPV) Asia Conference, Shanghai, China (March 25-27, 2010). The Westin Bund Center. Session 5 was held on March 26, 2010

Served as Chairperson of the session on “Novel Therapy in the Treatment of T2D” at the 5<sup>th</sup> World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Istanbul, Turkey on November 6, 2015.

Served as Chairperson of the session on “Outcome studies” at the 5<sup>th</sup> World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Istanbul, Turkey on November 7, 2015.

C. National Invited Lectures/Presentations:

“Evolving Concepts in the Prevention and Management of Cardiovascular Disease in Type 2 Diabetes.” Presented at a Satellite Symposium of the American Diabetes Association’s 60<sup>th</sup> Scientific Sessions entitled “The Continuing Education: New Insights into Diabetes Pathophysiology, Treatment, and CV Risk Evaluation,” June 10, 2001, San Antonio, TX.

“Model of Cardiovascular Aging in Macaca Fascicularis and Macaca Mulatta.” Presented at the Annual Meeting of the American Aging Association, “Successful Aging: Exploring Interventions for Maximizing Lifespan and Healthspan,” June 2001, Madison, WI.

“Simplifying Type 2 Diabetes Treatment: New Insulin Delivery Systems and Improved Patient Outcomes.” Presented at a Satellite Symposium of the 10<sup>th</sup> Anniversary Meeting and Clinical Congress of the American Association of Clinical Endocrinologists entitled “Mimicking Normal Physiology to Achieve Optimal Glycemic Control”, May 5, 2001, San Antonio, TX.

“Intensive Blood Glucose Control: Are All Anti-Hyperglycemic Agents Equal?” Presented at a Satellite Symposium of the 10<sup>th</sup> Anniversary Meeting and Clinical Congress of the American Association of Clinical Endocrinologists entitled “Re-examining the Beta Cell in Type 2 Diabetes,” May 4, 2001, San Antonio, TX.

“Insulin Secretagogues and the Management of Type 2 Diabetes.” Presented at a Satellite Symposium of the 61<sup>st</sup> Scientific Sessions of the American Diabetes Association entitled “Toward Optimal Management of Type 2 Diabetes Mellitus,” June 24, 2001, Philadelphia, PA.

“Insulin Use in Diabetes: Strategies for Surpassing Goals.” Presented at a Satellite Symposium of the 61<sup>st</sup> Scientific Sessions of the American Diabetes Association entitled “Will Using Insulin Earlier in Disease Progression Prevent Vascular Disease in Diabetes”, June 25, 2001, Philadelphia, PA.

“Disease-Modifying Therapy in Diabetes Prevention: Has Its Time Come?” Presented at a Satellite Symposium of the 62<sup>nd</sup> Scientific Sessions of the American Diabetes Association entitled “Challenging Disease Progression in Diabetes”, June 17, 2002, San Francisco, CA.

“Alternative Approaches to Insulin Therapy.” Presented at a Satellite Symposium of The Endocrine Society’s 84<sup>th</sup> Annual Meeting entitled “Mimicking Natural Physiology with Optimal Insulin Therapy,” June 21, 2002, San Francisco, CA.

“Non-Invasive Insulin Delivery Systems: Progress to Date.” Presented at a symposium of The Endocrine Society’s 84<sup>th</sup> Annual Meeting entitled “New Aspects of Insulin Therapy,” June 21, 2002, San Francisco, CA.

“Challenges and Rewards of Early and Intensive Insulin Treatment.” Presented at the American Association of Diabetes Educators’ 29<sup>th</sup> Annual Meeting and Exhibition in a Satellite Symposium entitled “Making Choices for Improved Quality of Life in Diabetes”, August 7, 2002, Philadelphia, PA

“Addressing Dual Defects: The Fundamentals of Therapy for Type 2 Diabetes”. Presented at the American Association of Diabetes Educators in the closing symposium entitled “Accentuate the Positive: Modern Approaches to Type 2 Diabetes”, August 10, 2002, Philadelphia, PA

“A Review of the Current Body of Scientific Evidence relating to Chromium Safety and Efficacy”. Presented at the American Association of Diabetes Educators in a Satellite symposium entitled “The Role of Chromium in the Prevention and Treatment of Insulin Resistance Management”, August 11, 2004, Indianapolis, Indiana.

“Therapeutic Strategies for Type 2 Diabetes: An Ever-Changing Landscape”. Presented at a Satellite Symposium of the 65<sup>th</sup> Scientific Sessions of the American Diabetes Association entitled “Paradigm Shifts in the Management of Type 2 Diabetes”, June 11, 2005, San Diego, CA.

“The Current Diabetes Landscape: Where should we go from here”. Presented at a Satellite Symposium of the 15<sup>th</sup> Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists in Chicago, Ill on April 28<sup>th</sup>, 2006. The symposium was entitled “Addressing Barriers to Glycemic Control: New Modalities to Improve Treatment and Adherence”.

“Update of Incretin Mimetics Clinical Trials”. Presented at a Satellite Symposium of the 15<sup>th</sup> Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists in Chicago, Ill on April 28<sup>th</sup>, 2006. The symposium was entitled “Examining the Future of Incretin Therapy: A Retrospective and Interpretive Analysis”.

“New Therapeutic Modalities to Achieve A1C goal”. Presented at a Satellite Symposium of the 66<sup>th</sup> Scientific Sessions of the American Diabetes Association entitled “New Therapeutic Modalities in Diabetes Care: Emerging Treatment Options to Attain A1C goal”, June 10, 2006, Washington, DC.

“The Link Between Type 2 Diabetes and Cardiovascular Disease”. Presented at a Satellite Symposium of the 66<sup>th</sup> Scientific Sessions of the American Diabetes Association entitled “Is There an Intrinsic Vascular Benefit to TZDs? Examining the Evidence”, June 11, 2006, Washington, DC.

“The Promise of Incretin Therapies: Data from Clinical Trials”. Presented at a Satellite Symposium of the 66<sup>th</sup> Scientific Sessions of the American Diabetes Association entitled “Debating the Management of Type 2 Diabetes with Emerging Therapies”, June 11, 2006, Washington, DC.

“Metabolic Effects of Inhaled Insulin”. Presented in a Symposium of the 66<sup>th</sup> Scientific

Sessions of the American Diabetes Association entitled “Inhaled Insulin-Metabolic and Pulmonary Issues”, June 13, 2006.

“Achieving and sustaining glycemic goals: Update on incretin hormone therapy” , Presented at the 2006 Post Graduate Update, Naples, Florida, August 4-6, 2006 for the American Association of Clinical Endocrinologists, The Florida Endocrine Society, Inc. Presented on August 4, 2006.

“Current Diabetes Landscape: Reassessing Strategies and Attitudes”, Presented at the 33<sup>rd</sup> Annual Meeting of the American Association of Diabetes Educators, August 11, 2006, Los Angeles, California.

“Cardiovascular Disease in Type 2 Diabetes: From Research to Clinical Practice”. Presented as part of a symposium entitled “The Butterfly Effect: Glycemic and Vascular Manifestations of Early, Aggressive Treatment in Type 2 Diabetes” in conjunction with The American College of Nurse Practitioners National Clinical Conference, Disney’s Coronado Springs Hotel, Orlando, Florida, October 12, 2006.

“Islet Cell Health and Glucose Homeostasis: What Roles Do Incretin Hormones Play?” Presented as part of a symposium entitled “The Role of Incretin Hormones in Diabetes Care: Meeting Old Challenges with New Advances” at the 2006 Southern Medical Association Annual Meeting, Charlotte Westin Hotel, Charlotte, North Carolina, October 12, 2006

“The Rationale for Early Intervention Treatment of Prediabetes and Early Stage Type 2 Diabetes for Positive Vascular Outcomes”. Presented as part of a symposium entitled “Realizing a Butterfly Effect: Predicting and Preventing Type 2 Diabetes and Related Vascular Disorders” in conjunction with the American Diabetes Association’s 54<sup>th</sup> Annual Advanced Postgraduate Course, Feb 23, 2007, New York, New York.

“Indications for Insulin Therapy: A Pathophysiologic Perspective”. Presented as part of a symposium entitled “Changing the Paradigm for Insulin Delivery: Innovations and Indications” in conjunction with the American Pharmacists Association’s 155<sup>th</sup> Annual Meeting and Exposition, March 16 – 19, 2007, Atlanta, Georgia. Presented on March 18, 2007

“New Insights into Type 2 Diabetes: The Impact of Incretin Hormone”. Presented in Session I entitled “Cardiovascular Disease in Patients with Diabetes: An Emerging Population at Risk” as part of the 20<sup>th</sup> Annual Scientific Sessions of the Association of Black Cardiologists, Inc, March 24<sup>th</sup> 2007. Theme of Scientific Sessions was “Compelling Issue in Cardiovascular Diseases 2007: Diabetes, New Imaging Technologies and Devices”.

“Therapeutic Advances and Additional Targets: Mechanisms of Action”. Presented as part of a symposium entitled “Building New Strategies: Interventions to Address the Vascular Consequences of Diabetes” as part of the American College of Cardiology’s 56<sup>th</sup> Annual Scientific Session, March 24-27, 2007, New Orleans, Louisiana. Presented on March 24, 2007.

“The Quest to Reach Glycemic Goal: The Role of Incretin-Based Therapeutic Strategies”. Presented at a Satellite Symposium held in conjunction with the 16<sup>th</sup> Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists in Seattle,

Washington on April 11<sup>th</sup>, 2007. The symposium was entitled “Achieving Glycemic Control and Preserving  $\beta$ -Cell Function.

“Alternative Approaches to Insulin Delivery”. Presented at a symposium at The American College of Physicians’ Internal Medicine 2007 meeting in San Diego, Ca. The symposium was entitled “The Future of Diabetes Care: The Impact of Inhaled Insulin on Glycemic Control”. Presented on April 19, 2007

“Metabolic Syndrome”. Presented at a Symposium at Experimental Biology 2007: “Today’s Research: Tomorrow’s Health” from April 28-May 2, Washington DC. Symposium was entitled “The Science of Botanical Supplements for Human Health: A view from the NIH Botanical Centers”. Presented on April 28<sup>th</sup>, 2007.

“The Promise of Incretin Therapy in Diabetes: Management for Today and Preventive Strategies for Tomorrow”. Presented at a symposium of The American Society of Hypertension (May 19-22, 2007) in Chicago, IL. The symposium was entitled “Diabetes/Insulin Resistance: Pathophysiology and Novel Therapies and the lecture was presented on May 22, 2007.

“Alternate Approaches to Insulin Delivery”. Presented at a Satellite Symposium of the 67th Scientific Sessions of the American Diabetes Association. The Symposium was entitled “The Future of Diabetes Care: The Impact of Inhaled Insulin on Glycemic Control”, June 22, 2007, Chicago, Ill.

“The Future of Insulin Therapy”. Presented at a Satellite Symposium of the 67th Scientific Sessions of the American Diabetes Association. The Symposium was entitled “Evolution of Insulin Therapy: Past, Current and Future Strategies”, June 22, 2007, Chicago, Ill.

“Incretin-Based Therapeutic Strategies: A Clinical Perspective”. Presented at a Satellite Symposium of the 67th Scientific Sessions of the American Diabetes Association. The Symposium was entitled “Emerging Developments with Incretin-Based Therapeutics: How will they impact the Management of Diabetes”, June 25, 2007, Chicago, Ill.

“What Role Do Incretin Therapeutics Play in Diabetes Management”. Presented at a Satellite Symposium of the 34<sup>th</sup> Annual Meeting of the American Association of Diabetes Educators. The Symposium was entitled “Multidisciplinary Interventions: Mapping New Horizons in Diabetic Care”, August 3, 2007, St. Louis, MO.

“Chromium: Is there a Role for Clinical Supplementation”, presented in a Symposium entitled “Micronutrients in Health and Disease: 2007 Update” at the 48<sup>th</sup> Annual Meeting of the American College of Nutrition, Orlando, Florida. Presented on September 28<sup>th</sup>, 2007

“Insulin Signaling Pathways: Glucose Metabolism in Health and Disease”, presented in a Symposium entitled “Molecular Mechanisms for Clinicians: Understanding the Basic Concepts” at the NAASO (North American Association for the Study of Obesity) The Obesity Society Annual Scientific Meeting 2007, New Orleans, Louisiana. Presented on October 22, 2007.

“Evolving Strategies in the Management of Diabetes: Controlling Glycemia and Insulin



Resistance”. Presented as part of a CME/CE certified satellite symposium entitled “Cardiovascular Risk in Diabetes: A Cross-specialty Approach to the Clinical Challenges”. American College of Cardiology’s 57<sup>th</sup> Annual Scientific Session, March 29-April 1, 2008, Chicago, Illinois. Presented on March 31, 2008.

“Incretin-based Therapeutic Options: Rationale and Supporting Data”. Presented at a Satellite Symposium held in conjunction with the 68<sup>th</sup> Scientific Sessions of the American Diabetes Association. The Symposium was entitled “Transformation of the Type 2 Diabetes Treatment Algorithm: The Incretin Effect”, Presented on June 8, 2008, San Francisco, CA.

“The Need for Novel Insulin Sensitizers”, Presented at a Satellite symposium held in conjunction with the 68<sup>th</sup> Scientific Sessions of the American Diabetes Association. The symposium was entitled “A New Path for Insulin Sensitizers: Inflammation, Macrophages and Insulin resistance. Presented on June 8, 2008, San Francisco, CA.

“Advancing Therapy in the Treatment of Type 2 Diabetes”. Presented at the 5<sup>th</sup> Annual Clinical Diabetes and Technology Meeting of the Diabetes Technology Society, Long Beach, California (April 3-4, 2009). The meeting was entitled “Technologies and Diabetes Monitoring and Therapy”. Presented on April 4, 2009 at the Westin Long Beach Hotel, Long Beach, CA.

“A Look at the Impact of Intensive Therapy on Microvascular and Macrovascular Complications “ Presented at a Satellite symposium held in conjunction with the 69<sup>th</sup> Scientific Sessions of the American Diabetes Association in New Orleans, Louisiana. The symposium was entitled “Managing Type 2 Diabetes: Perspectives on Evolving Treatment Standards and Gaps in Care.” Presented on June 6, 2009 at the New Orleans Marriott.

“Current and Emerging Strategies in the Multifaceted Management of Type 2 Diabetes”. Presented at a CME-certified Satellite symposium held in conjunction with the 69<sup>th</sup> Scientific Sessions of the American Diabetes Association in New Orleans, Louisiana. The symposium was entitled “Optimizing Glycemic Control and Risk Reduction”. Presented on June 8, 2009 at the New Orleans Marriott

“The Physiologic Role of Incretin Hormones: Clinical Applications”. Presented at a CME-certified Symposium held in conjunction with the 114<sup>th</sup> Annual Osteopathic Medical Conference and Exposition of the American Osteopathic Association (AOA) in New Orleans, Louisiana. The symposium was entitled “Advances in the Management of Type 2 Diabetes”. Presented on November 4<sup>th</sup>, 2009 at the New Orleans Hilton Riverside Hotel

“Alternative Delivery Methods for Insulin”. Presented at a symposium held as part of the 70<sup>th</sup> Scientific Sessions of the American Diabetes Association in New Orleans, Louisiana. The symposium was entitled “Newer Insulins- As they Approach Availability, what should we know about them”. Presented on June 27, 2010 at the Orlando Convention Center, Orlando, Florida.

“Alternative Insulin Delivery Systems – Inhaled, Oral, Patches, and Microneedles”. Presented at a symposium at the 73<sup>rd</sup> Scientific Sessions of the American Diabetes Association in Chicago, Illinois. The symposium was entitled, “Update on New Insulin Preparations for the Management of Diabetes.” Presented on June 23, 2013 at the McCormick Place Convention Center.

“Diabetes Care Profiles in Progress – Recognizing Pioneers in Clinical Diabetes Research.” Presented at the 75<sup>th</sup> Scientific Sessions of the American Diabetes Association in Boston, MA on June 6, 2015.

“Defining Prediabetes and Its Clinical Consequences – Do We Need a Better Alignment?” Presented at a professional interest group discussion at the 75<sup>th</sup> Scientific Sessions of the American Diabetes Association in Boston, MA on June 8, 2015.

“COBREs, INBREs, and IDeA-CTRs: Facilitating collaborations and interactions”. Presented at the NISBRE – NIH/NIGMS National IDeA Symposium in Washington, DC on June 29, 2016.

D. National Invited Moderator/Chairman:

“The Continuing Education: New Insights into Diabetes Pathophysiology, Treatment, and CV Risk Evaluation,” Satellite Symposium of the American Diabetes Association’s 60<sup>th</sup> Scientific Sessions, June 10, 2000, San Antonio, TX.

“Mimicking Normal Physiology to Achieve Optimal Glycemic Control,” Satellite Symposium of the 10<sup>th</sup> Anniversary Meeting and Clinical Congress of the American Association of Clinical Endocrinologists, May 5, 2001, San Antonio, TX.

“Toward Optimal Management of Type 2 Diabetes Mellitus,” Satellite Symposium of the American Diabetes Association’s 61<sup>st</sup> Scientific Sessions, June 24, 2001, Philadelphia, PA.

“Will Using Insulin Earlier in Disease Progression Prevent Vascular Disease in Diabetes?” Satellite Symposium of the American Diabetes Association’s 61<sup>st</sup> Scientific Sessions, June 24, 2001, Philadelphia, PA.

“Exploring the Controversy: Relative Roles of Postprandial and Fasting Plasma Glucose in Diabetes,” Satellite Symposium of the American Diabetes Association’s 62<sup>nd</sup> Scientific Sessions, June 18, 2002, San Francisco, CA.

“Mimicking Natural Physiology with Optimal Insulin Therapy,” Satellite Symposium of The Endocrine Society’s 84<sup>th</sup> Annual Meeting, June 21, 2002, San Francisco, CA.

“Update on Clinical Trials for Hypertension, Lipids and Glucose”. Moderated main session (June 7) during the 64<sup>th</sup> Annual Scientific Sessions of the American Diabetes Association Scientific Sessions, June 4-8, 2004, Orlando, Florida.

“Paradigm Shifts in the Management of Type 2 Diabetes”, Satellite Symposium of the 65<sup>th</sup> Annual Scientific Session, June 11, 2005, San Diego, CA.

“PPARs-Effects Beyond Glucose”. Moderated main session (June 11) during the 65<sup>th</sup> Annual Scientific Sessions of the American Diabetes Association, June 11-14, 2005, San Diego, CA

“The Future of Diabetes Care: The Impact of Inhaled Insulin on Glycemic Control”. Served

as Symposium Chairperson for the symposium presented at The American College of Physicians' Internal Medicine 2007 meeting held in San Diego, Ca. Symposium was held on April 19, 2007.

"The Future of Diabetes Care: The Impact of Inhaled Insulin on Glycemic Control". Served as Symposium Chairperson for the symposium presented at the 67th Scientific Sessions of the American Diabetes Association in Chicago, Ill. The Symposium was held on June 22, 2007, Chicago, Ill.

"A New Path for Insulin Sensitizers: Inflammation, Macrophages and Insulin Resistance. Served as Symposium Chairperson for the symposium presented at the 68th Scientific Sessions of the American Diabetes Association in San Francisco, CA, June 8, 2008.

"Pharmacotherapies for the Treatment of Type 2 Diabetes--From the Old to the New Served as Symposium Chairperson for the symposium presented at the 70th Scientific Sessions of the American Diabetes Association in Orlando, Florida, June 26, 2010.

"Diabetes". Served as Chairperson for the Scientific Session on *Diabetes* at The Obesity Society Annual Meeting in Atlanta, Georgia, November 14, 2013.

"Novel Clinical Interventions in Therapy that Impact the Management of Diabetes". Served as chair of the ADA *Diabetes Care* Symposium at the 75th Scientific Sessions of the American Diabetes Association in Boston, MA, June 6, 2015.

"Novel Translational Strategies in the Management of Diabetes." Served as chair of the ADA *Diabetes Care* Symposium at the 76th Scientific Sessions of the American Diabetes Association in New Orleans, LA, June 11, 2016.

#### E. Other Invited Lectures/Presentations:

"Inhaled Insulin- An Update and A Look Forward". Presented at the Second Annual Clinical Diabetes Technology Meeting from April 21-22, 2006 in Boston, Mass. Lecture was presented as part of the Insulin Delivery Strategies session held on April 22<sup>nd</sup>.

"What's New in Type 2 Diabetes? Lots!" . Presented on May 13, 2006 at "The New Drug Update" conference held in Charleston, South Carolina from May 11-13, 2006. The conference was presented by the Medical University of South Carolina's Department of Family Medicine, College of Pharmacy and College of Nursing.

"Inhaled Insulins", Presented on May 19, 2006 at the Cleveland Clinic's 11th Annual Diabetes Day 2006 in Cleveland, Ohio. The theme of the Symposium was entitled "Conquering Diabetes: What is New?"

"Metabolic Syndrome and Insulin Resistance: Progress toward developing high-throughput screening assays for botanical compounds". Presented as keynote address on August 5, 2007 at a research conference sponsored by The Jackson Laboratory. The conference was entitled "Discovery Strategies Conference: Modeling Human Metabolic Syndrome and Type

2 Diabetes in Rodents”, August 5-7, 2007, Bar Harbor, Maine.

“Update on Inhaled Insulin”, presented in a symposium entitled “Prandial Insulin and Cardiovascular Risk” at the Cardiometabolic Health Congress 2007, Sheraton Boston Hotel, Boston, Ma. Presented on September 26, 2007.

“Nutritional Management of Type 2 Diabetes: It’s not Just Calories Anymore. Presented at the 11<sup>th</sup> Annual Diabetes Update, Oklahoma Diabetes Center, The University of Oklahoma. Presented on November 14, 2008 in Oklahoma City, OK.

“Nutrition, Obesity and Diabetes”. Presented at the 2<sup>nd</sup> Annual Diabetes Today and Tomorrow Conference, Juvenile Diabetes Research Foundation International. Presented at the Burton Manor, Livonia, Michigan on May 30, 2009

“Emerging Treatments in the Management of Type 2 Diabetes”. Presented in the Joint China-Finland-PBRC Type 2 Diabetes Symposium, Pennington Biomedical Research Center, June 10, 2009

“Diabetes: From Bench Back to Bedside”. Presented at the Merck-Merial-NIH National Veterinary Scholars Symposium, North Carolina State University, August 7-8, 2009. Presented in “State of the Art Session A: Obesity”, Friday August 7, 2009

“Cardiometabolic Risk Reduction: Using Risk Assessment to Trigger Treatment”. Presented at a Joslin Diabetes Center Cardiometabolic CME Forum entitled “Identification and Reduction of Cardiometabolic Risk: Multifaceted Interventions for Office Practice”. Presented on April 10, 2010 in Atlanta, Georgia (Westin Buckhead).

“Advances in Type 2 Diabetes Management”. Presented at the 10<sup>th</sup> Annual Rocky Mountain Metabolic Syndrome Symposium. Presented on April 25, 2013 in Aurora, Colorado.

“Initiating and Titrating Insulin Therapy in Type 2 Diabetes”. Presented at the 10<sup>th</sup> Annual Rocky Mountain Metabolic Syndrome Symposium. Presented on April 25, 2013 in Aurora, Colorado.

“Nutraceuticals and Natural Treatments”. Presented at the Diabetes Initiative of South Carolina 19<sup>th</sup> Annual Diabetes Fall Symposium for Primary Health Care Professionals. Presented on September 19, 2013 at the North Charleston Convention Center, Charleston, South Carolina.

“Nutraceuticals and Botanical Therapies”. Presented at the American Diabetes Association’s 11<sup>th</sup> Annual Professional Education Symposium: Traditional and Non-Traditional Approaches to Diabetes Care. Presented on October 26, 2013 at The Queen’s Medical Center in The Queen’s Conference Center, Honolulu, Hawaii.

“Metabolic Dysregulation and Insulin Action: Insight from Human Phenotyping and Skeletal Muscle Lipid Metabolism Studies”. Presented as the Josiah Brown Memorial Lecturer in Diabetes Research on October 30, 2013 at the University of California-Los Angeles, Department of Medicine Grand Rounds, Los Angeles, California.

“A Paradigm Shift in the Approach to Research on Bioactive Compounds”. Presented as the Josiah Brown Memorial Lecturer in Diabetes Research on October 30, 2013 at the University of California-Los Angeles, Combined Endocrine Grand Rounds, Los Angeles, California.

“Identifying Pre-diabetes, the Cardiovascular Complications of Not Treating Pre-diabetes and Pre-diabetes from the Community Perspective”. Presented at the Diabetes Foundation of Mississippi Continuing Medical Education course on February 28, 2014 in Tupelo, Mississippi.

“The Art of Individualizing Therapy for Type 2 Diabetes”. Presented at the Diabetes Foundation of Mississippi Continuing Medical Education course on February 28, 2014 in Tupelo, Mississippi.

“Insight into Metabolic Dysregulation contributing to Insulin Resistance: Role of phenotype and muscle lipid content”. Presented at the University of Southern California Diabetes and Obesity Research Visiting Speaker Seminar on September 25, 2014 in Los Angeles, California.

“Enhancing multi-institutional translational research in Louisiana”. Presented at the Children’s Hospital Grand Rounds session on January 14, 2015 in New Orleans, Louisiana.

“Insight into Metabolic Dysregulation Contributing to Insulin Resistance: Role of phenotype and muscle lipid content”. Presented at the LSU Health Sciences Center Dean’s Research Seminar on January 14, 2015 in New Orleans, Louisiana.

“Identifying Pre-diabetes, the Cardiovascular Complications of Not Treating Pre-diabetes and Pre-diabetes from the Community Perspective”. Presented at the Diabetes Foundation of Mississippi Continuing Medical Education course on March 19, 2015 in Jackson, Mississippi.

“The Art of Individualizing Therapy for Type 2 Diabetes”. Presented at the Diabetes Foundation of Mississippi Continuing Medical Education course on March 19, 2015 in Jackson, Mississippi.

“The Art of Individualizing Therapy for Type 2 Diabetes”. Presented at the American Association of Clinical Endocrinologists meeting on January 22, 2016 in New Orleans, Louisiana.

“Metabolic Dysregulation and Insulin Action: Lessons Learned from Human Phenotyping”. Presented at University of Florida, Division of Endocrinology, Diabetes and Metabolism Grand Rounds on February 17, 2016 in Gainesville, Florida.

“Identifying Pre-diabetes, the Cardiovascular Complications of Not Treating Pre-diabetes and Pre-diabetes from the Community Perspective”. Presented at the Diabetes Foundation of Mississippi Continuing Medical Education course on March 4, 2016 in Gulfport, Mississippi.

“The Art of Individualizing Therapy for Type 2 Diabetes”. Presented at the Diabetes

Foundation of Mississippi Continuing Medical Education course on March 4, 2016 in Gulfport, Mississippi.

“Recognition and Management of Pre-Diabetes: Evolving Concepts for Intervention”. Presented at the UC Irvine Nephrology Grand Rounds, October 9, 2017

“Facing New Horizons: Optimism and Opportunities in Diabetes Management”. Presented at UC Irvine Department of Medicine Grand Round, October 10, 2017